https://curecurrent.com/trials/safety-of-rg2077-in-patients-with-multiple-sclerosis-107006https://curecurrent.com/trials/efficacy-and-safety-study-of-prolonged-release-fampridine-in-participants-with-multiple-sclerosis-107007https://curecurrent.com/trials/effect-of-md1003-in-spinal-progressive-multiple-sclerosis-107008https://curecurrent.com/trials/observational-study-to-characterize-real-world-clinical-outcomes-with-relapsing-remitting-multiple-sclerosis-rrms-107009https://curecurrent.com/trials/study-of-white-blood-cells-in-the-cerebrospinal-fluid-and-blood-of-patients-with-relapsing-forms-of-multiple-sclerosis-107010https://curecurrent.com/trials/pilot-study-to-assess-dimethyl-fumarate-related-gi-symptom-mitigation-107011https://curecurrent.com/trials/long-term-follow-up-of-fingolimod-phase-ii-study-patients-107012https://curecurrent.com/trials/pharmacokinetics-of-dmf-and-the-effects-of-dmf-on-exploratory-biomarkers-107013https://curecurrent.com/trials/safety-of-xeomin-for-lower-limb-spasticity-in-multiple-sclerosis-patients-107014https://curecurrent.com/trials/bg00012-phase-2-combination-study-in-participants-with-multiple-sclerosis-107015https://curecurrent.com/trials/a-prospective-open-label-non-randomized-clinical-trial-to-determine-if-natalizumab-tysabri-improves-ambulatory-measures-107016https://curecurrent.com/trials/open-label-study-to-assess-the-effect-of-long-term-prolonged-release-fampridine-biib041-on-quality-of-life-as-reported-b-107017https://curecurrent.com/trials/natalizumab-re-initiation-of-dosing-107018https://curecurrent.com/trials/phase-4-gastrointestinal-tolerability-study-of-dimethyl-fumarate-in-patients-with-relapsing-forms-of-multiple-sclerosis-107019https://curecurrent.com/trials/a-safety-and-efficacy-study-of-oral-prolonged-release-fampridine-biib041-in-japanese-participants-with-multiple-sclerosi-107020https://curecurrent.com/trials/fingolimod-versus-interferon-beta-1b-in-cognitive-symptoms-107021https://curecurrent.com/trials/atacicept-in-multiple-sclerosis-extension-study-phase-ii-107022https://curecurrent.com/trials/an-open-label-immunogenicity-and-pharmacokinetics-study-of-daclizumab-high-yield-process-prefilled-syringe-in-relapsing-107023https://curecurrent.com/trials/assessment-of-strategies-for-the-management-of-flu-like-symptoms-in-ms-patients-commencing-treatment-with-betaferon-infl-107024https://curecurrent.com/trials/safety-of-new-formulation-of-glatiramer-acetate-107025https://curecurrent.com/trials/everolimus-rad001-therapy-for-epilepsy-in-patients-with-tuberous-sclerosis-complex-tsc-107026https://curecurrent.com/trials/phase-iii-study-with-teriflunomide-versus-placebo-in-patients-with-first-clinical-symptom-of-multiple-sclerosis-107027https://curecurrent.com/trials/long-term-follow-up-of-patients-who-participated-in-study-27025-reflex-107028https://curecurrent.com/trials/rebif-rebidose-versus-rebiject-ii-ease-of-use-107029https://curecurrent.com/trials/effects-of-meditation-on-multiple-sclerosis-and-peripheral-neuropathy-107030https://curecurrent.com/trials/effect-of-aerobic-exercise-on-side-effects-of-disease-modifying-therapy-with-subcutaneous-interferon-b1b-in-patients-wit-107031https://curecurrent.com/trials/minocycline-in-clinically-isolated-syndromes-cis-107032https://curecurrent.com/trials/lido-workset-study-107033https://curecurrent.com/trials/assess-safety-bio-distribution-radiation-dosimetry-and-optimize-the-imaging-protocol-of-geh120714-18f-injection-in-healt-107034https://curecurrent.com/trials/tolerability-and-safety-and-health-outcomes-in-relapsing-multiple-sclerosis-ms-patients-107035https://curecurrent.com/trials/flextoba-for-people-with-multiple-sclerosis-107036https://curecurrent.com/trials/applications-of-nanotechnology-in-multiple-sclerosis-by-respiratory-samples-107037https://curecurrent.com/trials/the-effects-of-tysabri-treatment-on-vaccination-response-and-lymphocyte-subsets-in-subjects-with-relapsing-forms-of-mult-107038https://curecurrent.com/trials/11c-pbr28-positron-emission-tomography-study-to-evaluate-the-effect-of-abt-555-in-subjects-with-relapsing-forms-of-multi-107039https://curecurrent.com/trials/a-study-to-evaluate-the-impact-of-using-warm-compress-prior-to-daily-injections-of-copaxone-107040https://curecurrent.com/trials/lipoic-acid-for-secondary-progressive-multiple-sclerosis-ms-107041https://curecurrent.com/trials/phase-iii-trial-of-topical-formulation-of-sirolimus-to-skin-lesions-in-patients-with-tuberous-sclerosis-complex-tsc-107042https://curecurrent.com/trials/multicenter-validation-of-the-evergreen-myometric-strength-test-for-lower-extremities-emst-le-in-multiple-sclerosis-prot-107043https://curecurrent.com/trials/assessment-of-ocrelizumab-ocr-treatment-effects-on-functional-impairment-of-ms-patients-enrolled-in-the-phase-iii-orches-107044https://curecurrent.com/trials/long-term-safety-and-efficacy-study-of-teriflunomide-7-mg-or-14-mg-in-patients-with-relapsing-remitting-multiple-scleros-107045https://curecurrent.com/trials/tolerability-and-quality-of-life-study-in-participants-who-switched-to-avonex-pen-107046https://curecurrent.com/trials/defining-the-anti-inflammatory-role-of-lipoic-acid-in-multiple-sclerosis-107047https://curecurrent.com/trials/vitamin-d3-and-the-stress-axis-in-ms-107048https://curecurrent.com/trials/characterize-flu-like-symptoms-in-relapsing-multiple-sclerosis-patients-transitioning-from-non-pegylated-interferon-beta-107049https://curecurrent.com/trials/resound-rebif-satisfaction-on-discontinuing-oral-dimethyl-fumarate-107050https://curecurrent.com/trials/respiratory-function-and-walking-capacity-in-multiple-sclerosis-107051https://curecurrent.com/trials/a-study-to-evaluate-the-safety-and-tolerability-of-pf-06342674-rn168-in-subjects-with-multiple-sclerosis-ms-107052https://curecurrent.com/trials/long-term-safety-and-efficacy-study-of-peginterferon-beta-1a-107053https://curecurrent.com/trials/dose-escalation-study-of-t-cell-vaccine-in-multiple-sclerosis-107054https://curecurrent.com/trials/study-of-tcelna-imilecleucel-t-in-secondary-progressive-multiple-sclerosis-107055https://curecurrent.com/trials/exploratory-study-to-assess-the-effect-of-fampridine-biib041-on-walking-ability-and-balance-in-participants-with-multipl-107056https://curecurrent.com/trials/safety-and-efficacy-of-natalizumab-in-the-treatment-of-multiple-sclerosis-107057https://curecurrent.com/trials/safety-study-of-biib033-in-subjects-with-multiple-sclerosis-107058https://curecurrent.com/trials/alternative-treatment-paradigm-for-natalizumab-trial-107059https://curecurrent.com/trials/characteristics-and-predictors-of-progression-of-an-egyptian-multiple-sclerosis-cohort-107060https://curecurrent.com/trials/efficacy-and-safety-of-gtr-in-comparison-to-copaxone-107061https://curecurrent.com/trials/phase-4-study-of-effect-of-aspirin-on-flushing-in-dimethyl-fumarate-treated-participants-with-relapsing-remitting-multip-107062https://curecurrent.com/trials/multiple-sclerosis-produces-cardiovascular-subclinical-dysfunction-107063https://curecurrent.com/trials/efficacy-and-safety-of-vatelizumab-in-patients-with-relapsing-remitting-multiple-sclerosis-107064https://curecurrent.com/trials/efficacy-and-safety-of-vatelizumab-in-patients-who-completed-treatment-in-study-dri13839-107065https://curecurrent.com/trials/phase-i-ii-clinical-trial-with-autologous-bone-marrow-derived-mesenchymal-stem-cells-for-the-therapy-of-multiple-scleros-107066https://curecurrent.com/trials/evaluation-of-potential-accumulation-of-gadolinium-dotarem-and-multihance-in-the-french-observatory-of-multiple-sclerosi-107067https://curecurrent.com/trials/self-management-program-based-on-physical-exercises-in-people-with-multiple-sclerosis-107068https://curecurrent.com/trials/pharmacokinetics-safety-and-tolerability-of-single-doses-of-biib033-opicinumab-produced-by-2-manufacturing-processes-107069https://curecurrent.com/trials/preliminary-study-for-selective-detection-of-the-cd8-myelin-specific-t-cell-in-the-blood-of-multiple-sclerosis-patients-107070https://curecurrent.com/trials/using-patient-reported-outcomes-pros-to-evaluate-teriflunomide-treatment-in-relapsing-multiple-sclerosis-rms-patients-107071https://curecurrent.com/trials/post-transfusion-platelet-count-107072https://curecurrent.com/trials/supplementation-of-vigantol-oil-versus-placebo-as-add-on-in-patients-with-relapsing-remitting-multiple-sclerosis-receivi-107073https://curecurrent.com/trials/rehabilitation-in-multiple-sclerosis-influence-of-exercise-on-development-of-insulin-resistance-muscle-power-and-aerobic-107074https://curecurrent.com/trials/intrathecal-therapy-with-monoclonal-antibodies-in-progressive-multiple-sclerosis-107075https://curecurrent.com/trials/safety-study-of-olesoxime-in-patients-with-stable-relapsing-remitting-multiple-sclerosis-treated-with-interferon-beta-107076https://curecurrent.com/trials/demographics-clinical-and-paraclinical-characteristics-of-multiple-sclerosis-in-egypt-107077https://curecurrent.com/trials/biomarker-study-after-initiation-of-treatment-with-fingolimod-fty720-in-patients-with-relapsing-remitting-multiple-scler-107078https://curecurrent.com/trials/a-study-of-the-effect-of-fty720-on-pulmonary-function-in-patients-with-moderate-asthma-107079https://curecurrent.com/trials/fingolimod-response-according-to-coping-evaluation-107080https://curecurrent.com/trials/role-of-neuromuscular-junction-function-in-motor-fatigue-in-multiple-sclerosis-107081https://curecurrent.com/trials/neurorehabilitation-on-upper-limb-and-on-fatigue-in-multiple-sclerosis-107082https://curecurrent.com/trials/a-pilot-study-to-assess-microrna-biomarkers-in-early-and-later-stage-multiple-sclerosis-107083https://curecurrent.com/trials/impact-of-tecfidera-on-gut-microbiota-107084https://curecurrent.com/trials/upper-limbs-intervention-in-multiple-sclerosis-107085https://curecurrent.com/trials/plantar-pressure-distribution-in-patient-with-multiple-sclerosis-107086https://curecurrent.com/trials/computerized-cognition-testing-and-cognitive-motor-interference-in-ms-107087https://curecurrent.com/trials/tecfidera-diffusion-tensor-imaging-107088https://curecurrent.com/trials/cognitive-motor-interference-rehabilitation-in-persons-with-multiple-sclerosis-107089https://curecurrent.com/trials/evaluate-the-effect-of-switching-from-daily-injections-of-20mg-glatiramer-acetate-ga-to-40mg-ga-three-times-a-week-in-su-107090https://curecurrent.com/trials/assessing-relapse-in-multiple-sclerosis-arms-questionnaire-107091https://curecurrent.com/trials/fampridine-pregnancy-exposure-registry-107092https://curecurrent.com/trials/effects-of-cognitive-behavioural-therapy-and-exercise-on-stress-and-cognitive-deficits-in-multiple-sclerosis-107093https://curecurrent.com/trials/safety-tolerability-and-pharmacokinetics-of-single-and-multiple-doses-of-biib033-in-healthy-japanese-participants-107094https://curecurrent.com/trials/nanocort-in-acute-exacerbation-of-relapsing-remitting-multiple-sclerosis-ms-107095https://curecurrent.com/trials/jc-virus-jcv-antibody-program-107096https://curecurrent.com/trials/jc-virus-antibody-study-of-participants-with-relapsing-forms-of-ms-receiving-treatment-with-natalizumab-107097https://curecurrent.com/trials/autologous-stem-cell-transplant-for-multiple-sclerosis-107098https://curecurrent.com/trials/functional-electrical-stimulation-for-people-with-multiple-sclerosis-who-experience-foot-drop-107099https://curecurrent.com/trials/virtual-reality-and-robot-assisted-gait-training-in-patients-with-multiple-sclerosis-107100https://curecurrent.com/trials/safety-and-brain-protection-effects-of-the-green-tea-extract-theaphenon-95-95-pure-egcg-in-multiple-sclerosis-107101https://curecurrent.com/trials/treatment-of-multiple-sclerosis-with-copaxone-and-albuterol-107102https://curecurrent.com/trials/treating-multiple-sclerosis-with-sirolimus-an-immune-system-suppressor-107103https://curecurrent.com/trials/assistive-device-training-in-multiple-sclerosis-107104https://curecurrent.com/trials/a-cooperative-clinical-study-of-abatacept-in-multiple-sclerosis-107105https://curecurrent.com/trials/disease-control-in-rrms-transferring-treatment-from-natalizumab-to-fingolimod-107106https://curecurrent.com/trials/dose-finding-study-of-mt-1303-107107https://curecurrent.com/trials/electrophysiological-study-of-spatiotemporal-gait-parameters-in-patients-in-early-stage-of-multiple-sclerosis-107108https://curecurrent.com/trials/effects-of-ge-o-system-on-gait-impairments-in-multiple-sclerosis-subjects-107109https://curecurrent.com/trials/msfc-versus-dam-a-smartphone-application-for-multiple-sclerosis-self-assessment-107110https://curecurrent.com/trials/effects-of-electromechanical-gait-trainer-in-patients-with-multiple-sclerosis-107111https://curecurrent.com/trials/treating-foot-drop-in-people-with-multiple-sclerosis-using-electrical-stimulation-107112https://curecurrent.com/trials/the-french-multiple-sclerosis-registry-107113https://curecurrent.com/trials/restoring-glutathione-synthesis-with-tecfidera-an-in-vivo-h-mrs-single-arm-study-at-7t-in-patients-with-rr-ms-107114https://curecurrent.com/trials/china-betaferon-adherence-coping-and-nurse-support-study-107115https://curecurrent.com/trials/impacts-of-different-training-modes-intense-versus-ordinary-on-the-immune-system-and-memory-functions-in-pwms-107116https://curecurrent.com/trials/safety-and-efficacy-extension-study-of-daclizumab-high-yield-process-dac-hyp-in-participants-with-multiple-sclerosis-who-107117https://curecurrent.com/trials/changes-in-speed-endurance-and-balance-in-women-patients-with-multiple-sclerosis-after-4-8-weeks-of-aquatic-exercise-tra-107118https://curecurrent.com/trials/tecfidera-lymphocyte-chart-review-107119https://curecurrent.com/trials/a-study-of-a4i-antagonist-in-patients-with-relapsing-multiple-sclerosis-107120https://curecurrent.com/trials/effect-of-transcutaneous-electrical-nerve-stimulation-on-cognition-in-multiple-sclerosis-patients-107121https://curecurrent.com/trials/tuberous-sclerosis-complex-facial-angiofibroma-skin-cream-107122https://curecurrent.com/trials/study-to-assess-whether-gsk239512-can-remyelinate-lesions-in-subjects-with-relapsing-remitting-multiple-sclerosis-107123https://curecurrent.com/trials/locomotor-training-in-persons-with-multiple-sclerosis-107124https://curecurrent.com/trials/phase-3-28-week-randomized-double-blind-placebo-controlled-safety-and-efficacy-study-of-nabiximols-as-an-add-on-therapy-107125https://curecurrent.com/trials/multimodel-magnetic-resonance-imaging-mri-of-multiple-sclerosis-and-neuromyelitis-optica-spectrum-disorders-107126https://curecurrent.com/trials/flavopiridol-in-treating-patients-with-relapsed-or-refractory-lymphoma-or-multiple-myeloma-107127https://curecurrent.com/trials/a-trial-to-investigate-the-effectiveness-of-testosterone-treatment-in-men-with-multiple-sclerosis-107128https://curecurrent.com/trials/expiratory-muscle-conditioning-in-multiple-sclerosis-using-magnetic-stimulation-107129https://curecurrent.com/trials/consolidation-interference-in-multiple-sclerosis-107130https://curecurrent.com/trials/a-study-to-assess-the-effects-of-mk0812-on-disease-activity-in-patients-with-relapsing-remitting-multiple-sclerosis-as-m-107131https://curecurrent.com/trials/the-effects-of-focal-vibration-on-spasticity-in-multiple-sclerosis-patients-107132https://curecurrent.com/trials/re-training-to-effort-re-according-to-the-severity-of-multiple-sclerosis-preliminary-assessments-based-on-fatigue-and-qu-107133https://curecurrent.com/trials/proof-of-concept-study-of-rhb-104-as-add-on-therapy-to-interferon-beta-1a-in-relapsing-remitting-multiple-sclerosis-rrms-107134https://curecurrent.com/trials/effectiveness-of-dmf-and-its-impact-on-pros-in-suboptimal-ga-responders-with-rms-107135https://curecurrent.com/trials/mechanisms-of-action-of-dimethyl-fumarate-tecfidera-in-relapsing-ms-107136https://curecurrent.com/trials/role-of-virtual-reality-in-ms-rehabilitation-107137https://curecurrent.com/trials/natalizumab-tysabri-re-initiation-of-dosing-107138https://curecurrent.com/trials/safety-and-efficacy-of-avp-923-for-pseudobulbar-affect-in-multiple-sclerosis-patients-107139https://curecurrent.com/trials/phase-2-extension-trial-in-patients-with-relapsing-remitting-multiple-sclerosis-rrms-107140https://curecurrent.com/trials/safety-and-efficacy-study-of-daclizumab-high-yield-process-dac-hyp-to-treat-relapsing-remitting-multiple-sclerosis-107141https://curecurrent.com/trials/efficacy-and-safety-of-biib019-daclizumab-high-yield-process-versus-interferon-1a-in-participants-with-relapsing-remitti-107142https://curecurrent.com/trials/an-efficacy-study-of-teriflunomide-in-participants-with-relapsing-multiple-sclerosis-107143https://curecurrent.com/trials/nanotechnology-for-detection-of-multiple-sclerosis-compared-to-autoimmune-and-neurological-diseases-by-exhaled-samples-107144https://curecurrent.com/trials/observational-study-for-assessment-of-the-effect-of-fampyra-on-the-manual-function-of-persons-with-multiple-sclerosis-107145https://curecurrent.com/trials/effect-of-an-internet-based-at-home-physical-training-protocol-on-quality-of-life-fatigue-functional-performance-aerobic-107146https://curecurrent.com/trials/pk-and-pd-study-of-natalizumab-in-pediatric-subjects-with-rrms-107147https://curecurrent.com/trials/efficacy-study-of-andrographis-paniculata-purified-standardized-extract-ape-in-patients-with-multiple-sclerosis-ms-107148https://curecurrent.com/trials/a-combination-trial-of-copaxone-plus-estriol-in-relapsing-remitting-multiple-sclerosis-rrms-107149https://curecurrent.com/trials/fingolimod-real-world-experience-the-french-grand-est-cohort-107150https://curecurrent.com/trials/psychometric-properties-mobility-measures-ms-107151https://curecurrent.com/trials/dual-task-cost-in-the-upper-limb-in-persons-with-multiple-sclerosis-107152https://curecurrent.com/trials/a-study-comparing-the-effectiveness-and-safety-of-teriflunomide-and-interferon-beta-1a-in-patients-with-relapsing-multip-107153https://curecurrent.com/trials/management-of-the-infusion-associated-reactions-in-rrms-patients-treated-with-lemtrada-107154https://curecurrent.com/trials/long-term-effect-of-fingolimod-on-circulating-immunocompetent-mononuclear-cells-in-patients-with-multiple-sclerosis-107155https://curecurrent.com/trials/a-12-month-open-label-multi-center-study-to-explore-the-health-outcomes-of-fty720-107156https://curecurrent.com/trials/real-world-outcomes-on-tecfidera-bg00012-dimethyl-fumarate-post-tysabri-bg00002-natalizumab-107157https://curecurrent.com/trials/immune-and-mirna-response-to-recombinant-interferon-beta-in-healthy-volunteers-and-patients-with-relapsing-remitting-mul-107158https://curecurrent.com/trials/transcutaneous-tibial-nerve-stimulation-of-patients-with-overactive-bladder-oab-syndrome-107159https://curecurrent.com/trials/study-to-compare-the-clinical-and-radiological-efficacy-of-625-mg-versus-1250-mg-of-oral-methylprednisolone-in-patients-107160https://curecurrent.com/trials/bladder-management-in-patients-with-multiple-sclerosis-optimizing-practice-patterns-107161https://curecurrent.com/trials/a-phase-2-study-of-atacicept-in-subjects-with-relapsing-multiple-sclerosis-atams-107162https://curecurrent.com/trials/dti-in-children-with-multiple-sclerosis-107163https://curecurrent.com/trials/natalizumab-temporary-discontinuation-study-107164https://curecurrent.com/trials/allocentric-memory-in-ms-and-resting-state-functional-mri-107165https://curecurrent.com/trials/step-it-up-an-exercise-and-behaviour-change-programme-for-people-with-multiple-sclerosis-107166https://curecurrent.com/trials/access-use-and-opinions-of-physiotherapy-and-rehabilitation-services-of-people-with-progressive-ms-in-the-uk-107167https://curecurrent.com/trials/a-database-study-to-estimate-the-risk-of-multiple-sclerosis-following-vaccination-with-arepanrix-in-manitoba-canada-107168https://curecurrent.com/trials/effect-of-physical-activity-in-fingolimod-treated-patients-pace-with-relapsing-remitting-multiple-sclerosis-107169https://curecurrent.com/trials/polymorphisms-of-interleukins-glypican-and-human-leukocyte-antigen-genes-and-treatment-response-in-multiple-sclerosis-107170https://curecurrent.com/trials/efficacy-safety-and-tolerability-of-plovamer-acetate-pathway-1-107171https://curecurrent.com/trials/study-of-electrical-impedance-myography-eim-in-als-107172https://curecurrent.com/trials/neuroretinal-biomarkers-in-neurodegenerative-diseases-107173https://curecurrent.com/trials/computerized-exercise-training-for-cognitive-remediation-in-adults-with-multiple-sclerosis-treated-with-gilenya-107174https://curecurrent.com/trials/trichuris-suis-ova-tso-in-recurrent-remittent-multiple-sclerosis-and-clinically-isolated-syndrome-107175https://curecurrent.com/trials/telerehabilitation-upper-extremity-for-neurological-disorders-107176https://curecurrent.com/trials/mspt-device-usability-study-107177https://curecurrent.com/trials/motivation-of-patients-diagnosed-with-multiple-sclerosis-to-become-citizen-researchers-107178https://curecurrent.com/trials/evaluation-of-the-autonomic-nervous-system-during-first-dosing-with-0-5mg-of-fingolimod-gilenya-in-patients-with-relapsi-107179https://curecurrent.com/trials/safety-and-efficacy-of-pravastatin-in-relapsing-remitting-multiple-sclerosis-107180https://curecurrent.com/trials/immune-globulin-intravenous-igiv-to-treat-relapsing-remitting-multiple-sclerosis-107181https://curecurrent.com/trials/brimonidine-tartrate-for-the-treatment-of-injection-related-erythema-107182https://curecurrent.com/trials/observational-study-of-rebismart-2-0-msdialog-in-subjects-with-remitting-multiple-sclerosis-adherqol-107183https://curecurrent.com/trials/immune-regulation-in-multiple-sclerosis-the-effect-of-glatiramer-acetate-on-microrna-expression-in-antigen-presenting-ce-107184https://curecurrent.com/trials/aerobic-exercise-and-flu-like-symptoms-following-interferon-beta-1a-injections-in-patients-with-multiple-sclerosis-107185https://curecurrent.com/trials/drug-drug-interaction-of-cladribine-and-pantoprazole-in-multiple-sclerosis-subjects-107186https://curecurrent.com/trials/a-first-in-human-single-ascending-dose-study-of-gz402668-in-patients-with-progressive-multiple-sclerosis-107187https://curecurrent.com/trials/placebo-controlled-study-of-the-efficacy-and-safety-of-bg00012-in-pediatric-subjects-with-relapsing-remitting-multiple-s-107188https://curecurrent.com/trials/extension-study-of-mt-1303-107189https://curecurrent.com/trials/effectiveness-of-dmf-dimethyl-fumarate-and-its-impact-on-pros-patient-reported-outcomes-in-treatment-naive-or-suboptimal-107190https://curecurrent.com/trials/proof-of-concept-study-evaluating-rns60-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-107191https://curecurrent.com/trials/comparison-of-intermittent-vs-continuous-walking-in-ms-107192https://curecurrent.com/trials/walking-with-fes-or-afo-in-people-with-ms-with-foot-drop-107193https://curecurrent.com/trials/lung-volume-recruitment-for-lung-function-and-cough-impairment-in-multiple-sclerosis-107194https://curecurrent.com/trials/autologous-mesenchymal-stem-cell-msc-transplantation-in-ms-107195https://curecurrent.com/trials/double-blind-combination-of-rituximab-by-intravenous-and-intrathecal-injection-versus-placebo-in-patients-with-low-infla-107196https://curecurrent.com/trials/efficacy-study-of-adrenocorticotropin-hormone-to-treat-multiple-sclerosis-ms-relapses-after-sub-responding-to-an-initial-107197https://curecurrent.com/trials/robot-based-rehabilitation-of-upper-limb-impairment-in-multiple-sclerosis-107198https://curecurrent.com/trials/open-label-extension-of-prior-terms-study-to-treat-relapsing-forms-of-multiple-sclerosis-107199https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-ain457-in-patients-with-relapsing-remitting-multiple-scleros-107200https://curecurrent.com/trials/evaluation-of-the-efficiency-of-a-cognitive-remedial-program-procog-sep-designed-for-multiple-sclerosis-patients-107201https://curecurrent.com/trials/the-effects-of-ankle-foot-orthoses-afos-on-mobility-in-persons-with-multiple-sclerosis-ms-107202https://curecurrent.com/trials/high-dose-oral-versus-intramuscular-vitamin-d3-supplementation-in-multiple-sclerosis-patients-107203https://curecurrent.com/trials/comparison-of-rebif-compared-to-tecifdera-on-six-month-outcomes-in-patients-with-relapsing-remitting-ms-107204https://curecurrent.com/trials/efficacy-safety-and-tolerability-of-nerispirdine-in-patients-with-multiple-sclerosis-107205https://curecurrent.com/trials/single-oral-doses-study-of-nerispirdine-on-visual-function-in-patients-with-multiple-sclerosis-107206https://curecurrent.com/trials/evaluating-intervention-responsiveness-in-people-with-multiple-sclerosis-107207https://curecurrent.com/trials/study-to-investigate-the-immune-response-to-influenza-vaccine-in-patients-with-multiple-sclerosis-on-teriflunomide-107208https://curecurrent.com/trials/a-rct-of-telephone-supported-act-in-ms-107209https://curecurrent.com/trials/centralized-reading-assessment-of-chronic-cerebrospinal-venous-insufficiency-ccsvi-in-patients-with-multiple-sclerosis-a-107210https://curecurrent.com/trials/th-effects-of-aubagio-on-brain-pathology-in-multiple-sclerosis-studied-over-12-months-107211https://curecurrent.com/trials/assessment-of-lesion-activity-analysis-in-the-avonex-steroid-azathioprine-asa-study-107212https://curecurrent.com/trials/randomised-controlled-clinical-trial-of-cognitive-rehabilitation-in-multiple-sclerosis-107213https://curecurrent.com/trials/18f-pbr111-and-microglial-activation-in-multiple-sclerosis-107214https://curecurrent.com/trials/study-of-fampridine-sr-tablets-in-multiple-sclerosis-patients-107215https://curecurrent.com/trials/progressive-muscle-relaxation-effect-on-sleep-quality-depression-and-stress-in-people-with-multiple-sclerosis-107216https://curecurrent.com/trials/efficacy-and-safety-of-everolimus-rad001-in-patients-of-all-ages-with-subependymal-giant-cell-astrocytoma-associated-wit-107217https://curecurrent.com/trials/wii-fit-balance-board-to-recording-balance-parameters-in-multiple-sclerosis-subjects-107218https://curecurrent.com/trials/assessing-tolerability-of-avonex-intramuscular-injections-107219https://curecurrent.com/trials/jc-virus-reactivation-in-multiple-sclerosis-107220https://curecurrent.com/trials/worms-for-immune-regulation-of-multiple-sclerosis-107221https://curecurrent.com/trials/acupuncture-or-mbsr-for-patients-with-fatigue-and-ms-107222https://curecurrent.com/trials/a-follow-on-study-to-assess-long-term-safety-and-tolerability-of-i-c-v-administration-of-snn0029-in-patients-with-als-107223https://curecurrent.com/trials/safety-and-tolerability-of-glatiramer-acetate-107224https://curecurrent.com/trials/extension-study-to-evaluate-safety-and-efficacy-of-natalizumab-in-japanese-participants-with-relapsing-remitting-multipl-107225https://curecurrent.com/trials/intrathecal-methotrexate-for-progressive-multiple-sclerosis-an-open-label-single-arm-study-107226https://curecurrent.com/trials/study-to-explore-the-onset-of-efficacy-on-magnetic-resonance-disease-activity-of-bg00012-dimethyl-fumarate-in-patients-w-107227https://curecurrent.com/trials/oral-prednisone-taper-versus-placebo-for-the-treatment-of-acute-relapses-in-multiple-sclerosis-107228https://curecurrent.com/trials/brave-dreams-brain-venous-drainage-exploited-against-multiple-sclerosis-107229https://curecurrent.com/trials/pacing-activity-self-management-for-patients-with-multiple-sclerosis-107230https://curecurrent.com/trials/a-safety-and-efficacy-study-of-elnd002-in-patients-with-relapsing-forms-of-multiple-sclerosis-107231https://curecurrent.com/trials/a-study-of-elnd002-in-patients-with-relapsing-forms-of-multiple-sclerosis-107232https://curecurrent.com/trials/comparison-of-safety-and-efficacy-of-tizanidine-hydrochloride-capsules-versus-zanaflex-tizanidine-hydrochloride-tablets-107233https://curecurrent.com/trials/acute-effect-of-fascial-mobilization-on-gait-in-patients-with-multiple-sclerosis-107234https://curecurrent.com/trials/lubiprostone-in-patients-with-multiple-sclerosis-associated-constipation-107235https://curecurrent.com/trials/memantine-for-spasticity-in-ms-patients-107236https://curecurrent.com/trials/characterization-of-the-effects-of-prolonged-release-fampridine-on-ambulatory-function-in-patients-with-multiple-scleros-107237https://curecurrent.com/trials/project-get-fit-with-ms-guidelines-for-exercise-training-and-fitness-outcomes-in-ms-107238https://curecurrent.com/trials/single-test-to-arrive-at-ms-diagnosis-using-a-single-mri-brain-scan-to-help-diagnose-multiple-sclerosis-107239https://curecurrent.com/trials/functional-changes-following-percutaneous-venoplasty-in-multiple-sclerosis-patients-107240https://curecurrent.com/trials/doxycycline-in-lymphangioleiomyomatosis-lam-107241https://curecurrent.com/trials/development-of-a-motivational-intervention-to-improve-treatment-adherence-in-ms-107242https://curecurrent.com/trials/development-of-a-talk-therapy-protocol-to-help-patients-make-treatment-decisions-in-ms-107243https://curecurrent.com/trials/mri-guided-focused-ultrasound-for-tremor-in-multiple-sclerosis-107244https://curecurrent.com/trials/computerized-cognitive-exercise-training-treatment-for-adults-with-multiple-sclerosis-107245https://curecurrent.com/trials/regional-cortical-cerebral-quantitative-mri-perfusion-correlation-neurocognition-in-multiple-sclerosis-107246https://curecurrent.com/trials/comparison-study-of-pf530-and-betaferon-in-healthy-subjects-107247https://curecurrent.com/trials/lokomat-treadmill-training-effects-on-ms-gait-107248https://curecurrent.com/trials/responsiveness-to-dalfampridine-er-treatment-among-multiple-sclerosis-patients-107249https://curecurrent.com/trials/a-study-of-allogeneic-human-uc-msc-and-liberation-therapy-when-associated-with-ccsvi-in-patients-with-rrms-107250https://curecurrent.com/trials/balance-and-falls-in-multiple-sclerosis-107251https://curecurrent.com/trials/deciphering-the-role-of-the-gut-microbiota-in-multiple-sclerosis-107252https://curecurrent.com/trials/open-label-study-to-evaluate-effect-safety-and-tolerability-of-betaferon-standard-dose-of-250-g-in-patients-of-chinese-o-107253https://curecurrent.com/trials/the-inflammatory-process-and-the-medical-imaging-in-patients-with-an-inflammatory-disease-of-the-central-nervous-system-107254https://curecurrent.com/trials/a-study-of-allogeneic-human-uc-msc-and-liberation-therapy-when-associated-with-ccsvi-in-patients-with-rrms-107255https://curecurrent.com/trials/a-study-of-autologous-bone-marrow-derived-mononuclear-stem-cells-bm-mnc-and-liberation-therapy-when-associated-with-ccsv-107256https://curecurrent.com/trials/safety-and-efficacy-in-pediatric-ms-patients-prescribed-tysabri-107257https://curecurrent.com/trials/avonex-evaluation-of-quality-of-life-and-convenience-in-belgian-participants-the-avail-study-107258https://curecurrent.com/trials/observational-study-to-analyse-the-impact-of-nurse-support-and-disease-related-factors-on-long-term-adherence-to-betafer-107259https://curecurrent.com/trials/pilot-study-to-assess-disease-stability-in-a-natalizumab-to-dimethyl-fumarate-crossover-design-107260https://curecurrent.com/trials/the-effect-of-levetiracetam-keppra-on-the-treatment-of-tremor-in-multiple-sclerosis-107261https://curecurrent.com/trials/open-multicentric-prospective-quality-of-life-study-in-multiple-sclerosis-patients-107262https://curecurrent.com/trials/observational-study-to-establish-patient-matched-population-norms-for-the-multiple-sclerosis-cognition-assessment-batter-107263https://curecurrent.com/trials/vitamin-d-pilot-study-in-patients-with-multiple-sclerosis-107264https://curecurrent.com/trials/botulinum-toxin-type-a-for-treating-allodynic-pain-in-sci-and-ms-107265https://curecurrent.com/trials/cognitive-behavior-therapy-for-ms-related-chronic-pain-107266https://curecurrent.com/trials/exercises-for-urinary-incontinence-ui-of-women-with-multiple-sclerosis-ms-107267https://curecurrent.com/trials/a-study-to-evaluate-the-safety-and-efficacy-of-rituximab-in-adults-with-primary-progressive-multiple-sclerosis-107268https://curecurrent.com/trials/neuroprotection-with-phenytoin-in-optic-neuritis-107269https://curecurrent.com/trials/study-to-evaluate-fatigue-in-participants-with-relapsing-remitting-multiple-sclerosis-when-treated-with-dimethyl-fumarat-107270https://curecurrent.com/trials/single-dose-study-of-a-new-formulation-of-biib061-107271https://curecurrent.com/trials/optic-neuritis-recovery-after-oral-or-iv-corticosteroids-107272https://curecurrent.com/trials/does-fampridine-sr-improve-cognitive-fatigue-in-multiple-sclerosis-patients-107273https://curecurrent.com/trials/a-study-to-evaluate-safety-and-efficacy-of-dc-tab-in-multiple-sclerosis-107274https://curecurrent.com/trials/fall-risk-reduction-in-multiple-sclerosis-firms-107275https://curecurrent.com/trials/exploratory-study-of-the-safety-tolerability-and-efficacy-of-multiple-regimens-of-natalizumab-in-adult-participants-with-107276https://curecurrent.com/trials/robot-assisted-gait-training-in-patients-with-multiple-sclerosis-efficacy-and-comparison-with-traditional-methods-107277https://curecurrent.com/trials/effectiveness-of-ankle-foot-orthoses-on-gait-in-multiple-sclerosis-107278https://curecurrent.com/trials/safety-and-efficacy-of-an-immunoablative-nonmyeloablative-conditioning-protocol-for-autologous-bone-marrow-transplantati-107279https://curecurrent.com/trials/melatonin-in-relapsing-remitting-multiple-sclerosis-patients-107280https://curecurrent.com/trials/placebo-vs-linoleic-acid-controlled-assessment-of-treatment-efficacy-in-ms-107281https://curecurrent.com/trials/influence-of-emotional-disorders-and-executive-on-the-components-retrograde-and-anterograde-episodic-memory-in-ms-107282https://curecurrent.com/trials/phase-i-bp-interferon-ifn-beta-004-107283https://curecurrent.com/trials/autologous-mesenchymal-stem-cells-from-adipose-tissue-in-patients-with-secondary-progressive-multiple-sclerosis-107284https://curecurrent.com/trials/phase-i-bp-interferon-ifn-beta-001-107285https://curecurrent.com/trials/use-of-an-electronic-diary-by-people-with-multiple-sclerosis-107286https://curecurrent.com/trials/follow-up-study-after-11-years-of-patients-who-were-included-in-the-benefit-trial-304747-with-a-first-demyelinating-even-107287https://curecurrent.com/trials/cytokine-in-cerebrospinal-fluid-csf-from-multiple-sclerosis-patients-107288https://curecurrent.com/trials/injection-management-with-betaferon-influence-on-adherence-patients-satisfaction-and-health-related-outcomes-betapath-107289https://curecurrent.com/trials/trial-of-analgesia-with-lidocaine-or-extended-release-oxycodone-for-neuropathic-pain-treatment-in-multiple-sclerosis-107290https://curecurrent.com/trials/rebif-new-formulation-rnf-in-relapsing-forms-of-multiple-sclerosis-107291https://curecurrent.com/trials/improving-gait-in-multiple-sclerosis-ms-strength-training-or-treadmill-walking-107292https://curecurrent.com/trials/d-mannose-for-the-prevention-of-utis-in-multiple-sclerosis-107293https://curecurrent.com/trials/comparison-between-clinical-and-mri-multiple-sclerosis-activity-and-expression-of-human-endogenous-retrovirus-type-w-and-107294https://curecurrent.com/trials/prospective-multicenter-non-interventional-study-to-evaluate-adherence-to-betaferon-over-a-2-years-period-107295https://curecurrent.com/trials/robot-assisted-training-of-the-upper-limb-in-persons-with-multiple-sclerosis-an-randomized-controlled-trial-107296https://curecurrent.com/trials/efficiency-of-4-aminopyridin-fampyra-on-gait-vision-cognition-fatigue-and-micturation-in-patients-with-multiple-sclerosi-107297https://curecurrent.com/trials/patients-with-relapse-remitting-multiple-sclerosis-rrms-candidates-for-ms-therapy-change-107298https://curecurrent.com/trials/tysabri-global-observational-program-in-safety-107299https://curecurrent.com/trials/multiple-sclerosis-rehabilitation-study-107300https://curecurrent.com/trials/efficacy-and-safety-of-ain457-secukinumab-in-patients-with-relapsing-multiple-sclerosis-107301https://curecurrent.com/trials/rehabilitation-study-in-ms-patients-107302https://curecurrent.com/trials/impact-of-disease-modifying-therapies-dmts-and-associated-support-services-in-relapsing-multiple-sclerosis-rms-patients-107303https://curecurrent.com/trials/retrospective-cohort-study-of-rebif-use-in-pediatric-multiple-sclerosis-ms-subjects-replay-107304https://curecurrent.com/trials/safety-and-dose-finding-study-of-dc-tab-in-healthy-subjects-107305https://curecurrent.com/trials/adderall-xr-and-processing-speed-in-multiple-sclerosis-ms-107306https://curecurrent.com/trials/methylphenidate-as-treatment-option-of-fatigue-in-multiple-sclerosis-107307https://curecurrent.com/trials/the-efficacy-of-botulinum-toxin-in-disabling-multiple-sclerosis-ms-tremor-107308https://curecurrent.com/trials/modulation-of-plasmacytoid-dendritic-cell-function-in-multiple-sclerosis-107309https://curecurrent.com/trials/the-cognitive-variability-in-nf1-and-tsc-monozygotic-twins-107310https://curecurrent.com/trials/efficacy-of-rad001-everolimus-in-autism-and-neuropsychological-deficits-in-children-with-tuberous-sclerosis-complex-107311https://curecurrent.com/trials/establish-tolerance-in-ms-with-peptide-coupled-peripheral-blood-mononuclear-cells-107312https://curecurrent.com/trials/a-study-to-test-the-use-of-duloxetine-for-pain-in-ms-107313https://curecurrent.com/trials/balance-training-for-people-with-multiple-sclerosis-using-nintendo-wii-fit-107314https://curecurrent.com/trials/beyond-follow-up-betaferon-betaseron-efficacy-yielding-outcomes-of-a-new-dose-107315https://curecurrent.com/trials/intensity-depended-impacts-on-cognitive-functions-in-persons-with-multiple-sclerosis-a-pilot-study-107316https://curecurrent.com/trials/transcranial-doppler-in-multiple-sclerosis-107317https://curecurrent.com/trials/improving-hand-use-in-multiple-sclerosis-107318https://curecurrent.com/trials/tygris-row-tysabri-global-observational-program-in-safety-rest-of-world-107319https://curecurrent.com/trials/three-months-treatment-with-sb683699-in-patients-with-relapsing-multiple-sclerosis-107320https://curecurrent.com/trials/a-single-blinded-controlled-multi-centre-study-of-effects-of-exercise-in-participants-with-multiple-sclerosis-107321https://curecurrent.com/trials/costs-quality-of-life-and-functional-outcomes-in-veterans-treated-for-multiple-sclerosis-with-beta-interferon-l-b-betase-107322https://curecurrent.com/trials/takecharge-telephone-delivered-self-management-intervention-for-people-with-multiple-sclerosis-ms-107323https://curecurrent.com/trials/vascular-fundus-changes-in-patients-with-high-probability-of-chronic-cerebrospinal-venous-insufficiency-ccsvi-107324https://curecurrent.com/trials/analysis-of-a-biomarker-signature-in-patients-with-multiple-sclerosis-ms-treated-with-gilenya-fty720-107325https://curecurrent.com/trials/group-balance-training-for-people-with-multiple-sclerosis-107326https://curecurrent.com/trials/multiple-sclerosis-and-extract-of-cannabis-musec-study-107327https://curecurrent.com/trials/long-term-safety-and-efficacy-of-teriflunomide-hmr1726-in-multiple-sclerosis-with-relapses-107328https://curecurrent.com/trials/effectiveness-of-web-based-treatment-for-depression-in-patients-with-neurologic-disorders-107329https://curecurrent.com/trials/safety-and-tolerability-of-fingolimod-in-patients-with-relapsing-remitting-multiple-sclerosis-107330https://curecurrent.com/trials/falls-prevention-and-balance-rehabilitation-in-multiple-sclerosis-107331https://curecurrent.com/trials/mass-balance-study-of-mt-1303-107332https://curecurrent.com/trials/comparative-oral-bioavailability-study-of-mt-1303-107333https://curecurrent.com/trials/effect-of-teriflunomide-on-immune-cell-subsets-in-the-blood-of-patients-with-multiple-sclerosis-107334https://curecurrent.com/trials/study-to-compare-double-dose-betaferon-to-the-approved-dose-for-patients-with-early-secondary-progressive-multiple-scler-107335https://curecurrent.com/trials/continuous-intrathecal-baclofen-infusion-for-chronic-spasticity-107336https://curecurrent.com/trials/diclofenac-sodium-topical-gel-to-reduce-injection-site-discomfort-in-patients-taking-glatiramer-acetate-107337https://curecurrent.com/trials/poc-md-mri-based-trial-in-relapsing-remitting-multiple-scler-107338https://curecurrent.com/trials/an-intravenous-infusion-study-of-rhigm22-in-patients-with-multiple-sclerosis-107339https://curecurrent.com/trials/a-phase-1-study-to-explore-the-cardiac-pharmacodynamics-of-mt-1303-107340https://curecurrent.com/trials/canadian-avonex-pen-productivity-study-107341https://curecurrent.com/trials/phototherapy-in-persons-with-multiple-sclerosis-107342https://curecurrent.com/trials/atx-ms-1467-in-patients-with-relapsing-forms-of-multiple-sclerosis-107343https://curecurrent.com/trials/endovascular-treatment-for-chronic-cerebrospinal-venous-insufficiency-ccsvi-107344https://curecurrent.com/trials/a-pharmacokinetic-pk-study-of-natalizumab-tysabri-at-steady-state-107345https://curecurrent.com/trials/evaluation-of-safety-tolerability-and-pk-of-vx15-2503-in-patients-with-ms-107346https://curecurrent.com/trials/safety-pharmacokinetics-and-pharmacodynamics-study-with-2b3-201-in-healthy-subjects-and-multiple-sclerosis-ms-patients-107347https://curecurrent.com/trials/low-fat-diet-and-multiple-sclerosis-107348https://curecurrent.com/trials/physical-capacity-and-rehabilitation-of-patients-with-multiple-sclerosis-107349https://curecurrent.com/trials/study-to-evaluate-the-pharmacokinetic-profiles-of-biib017-peginterferon-beta-1a-and-rebif-interferon-beta-1a-in-healthy-107350https://curecurrent.com/trials/adherence-trial-with-ms-lifelines-services-107351https://curecurrent.com/trials/responsiveness-and-minimal-clinical-important-difference-of-the-multiple-sclerosis-questionnaire-for-physiotherapists-107352https://curecurrent.com/trials/efficacy-and-safety-of-oral-bg00012-in-relapsing-remitting-multiple-sclerosis-107353https://curecurrent.com/trials/efficacy-and-safety-study-of-oral-bg00012-with-active-reference-in-relapsing-remitting-multiple-sclerosis-107354https://curecurrent.com/trials/depression-and-fatigue-in-ms-patients-treated-with-betaferon-107355https://curecurrent.com/trials/a-phase-ii-study-comparing-low-and-high-dose-alemtuzumab-and-high-dose-rebif-in-patients-with-early-active-relapsing-rem-107356https://curecurrent.com/trials/spinal-direct-current-stimulation-effects-on-pain-in-multiple-sclerosis-107357https://curecurrent.com/trials/an-efficacy-and-safety-comparison-study-of-two-marketed-drugs-in-patients-with-relapsing-remitting-ms-107358https://curecurrent.com/trials/study-to-assess-immune-function-and-mri-disease-activity-in-rrms-patients-when-switching-from-natalizumab-to-gilenya-107359https://curecurrent.com/trials/body-weight-supported-treadmill-training-in-persons-with-multiple-sclerosis-107360https://curecurrent.com/trials/imaging-multiple-sclerosis-lesions-using-magnevist-and-gadavist-107361https://curecurrent.com/trials/exercise-as-a-strategy-to-treat-cognitive-dysfunction-in-persons-with-multiple-sclerosis-107362https://curecurrent.com/trials/nurse-led-manualized-telephone-support-intervention-107363https://curecurrent.com/trials/studying-the-effects-of-copaxone-on-retinal-health-using-optical-tomography-over-24-months-107364https://curecurrent.com/trials/impact-of-crisp-on-self-efficacy-loneliness-and-depression-107365https://curecurrent.com/trials/multiple-sclerosis-and-progressive-resistance-training-107366https://curecurrent.com/trials/study-of-darifenacin-in-patients-suffering-from-multiple-sclerosis-and-neurogenic-detrusor-overactivity-107367https://curecurrent.com/trials/fall-risk-reduction-in-multiple-sclerosis-exercise-versus-behavior-107368https://curecurrent.com/trials/project-farms-fall-risk-reduction-in-multiple-sclerosis-107369https://curecurrent.com/trials/chronotherapy-in-acute-multiple-sclerosis-ms-attack-107370https://curecurrent.com/trials/comparison-of-alemtuzumab-and-rebif-efficacy-in-multiple-sclerosis-study-one-107371https://curecurrent.com/trials/phase-ib-study-to-evaluate-mor103-in-multiple-sclerosis-107372https://curecurrent.com/trials/mindfulness-based-stress-reduction-in-multiple-sclerosis-ms-107373https://curecurrent.com/trials/transition-to-peginterferon-beta-1a-biib017-from-subcutaneous-interferon-therapy-107374https://curecurrent.com/trials/an-observational-study-on-the-progression-of-clinically-isolated-syndrome-to-multiple-sclerosis-over-a-2-year-period-107375https://curecurrent.com/trials/antispastic-effect-of-transcranial-magnetic-stimulation-in-patients-with-cerebral-and-spinal-spasticity-107376https://curecurrent.com/trials/study-to-evaluate-the-reduction-of-cardiac-problems-in-multiple-sclerosis-patients-with-mitoxantrone-and-dexrazoxane-in-107377https://curecurrent.com/trials/pilot-study-of-free-from-falls-program-in-multiple-sclerosis-107378https://curecurrent.com/trials/efficacy-safety-and-tolerability-of-andrographolides-versus-placebo-in-patients-with-progressive-forms-of-ms-107379https://curecurrent.com/trials/natalizumab-bg00002-tysabri-study-in-japanese-participants-with-relapsing-remitting-multiple-sclerosis-rrms-107380https://curecurrent.com/trials/everolimus-rad001-therapy-of-giant-cell-astrocytoma-in-patients-with-tuberous-sclerosis-complex-107381https://curecurrent.com/trials/exercise-intensity-and-immune-function-in-multiple-sclerosis-107382https://curecurrent.com/trials/treadmill-training-in-chronic-ms-efficacy-and-cost-effectiveness-107383https://curecurrent.com/trials/efficacy-of-dalfampridine-on-upper-extremity-function-in-patients-with-ms-107384https://curecurrent.com/trials/effect-of-an-individualized-patient-support-program-on-treatment-satisfaction-in-fingolimod-treated-patients-with-rrms-107385https://curecurrent.com/trials/combination-of-antidepressants-and-fingolimod-relapsing-remitting-multiple-sclerosis-rrms-patients-with-depression-107386https://curecurrent.com/trials/efficacy-and-safety-study-of-peginterferon-beta-1a-in-participants-with-relapsing-multiple-sclerosis-107387https://curecurrent.com/trials/safety-and-efficacy-of-bmmnc-in-multiple-sclerosis-ms-107388https://curecurrent.com/trials/pilot-clinical-trial-of-acthar-gel-14-days-subcutaneous-sq-versus-acthar-gel-five-days-sq-for-the-treatment-of-ms-exacer-107389https://curecurrent.com/trials/using-optical-coherence-tomography-oct-to-evaluate-the-efficacy-and-safety-of-pegylated-interferon-beta-1a-biib017-in-pa-107390https://curecurrent.com/trials/brain-functional-connectivity-changes-following-cognitive-rehabilitation-in-multiple-sclerosis-an-fmri-study-107391https://curecurrent.com/trials/safety-study-of-natalizumab-to-treat-multiple-sclerosis-ms-107392https://curecurrent.com/trials/persistence-adherence-quality-of-life-and-treatment-satisfaction-with-avonex-pen-107393https://curecurrent.com/trials/study-evaluating-rebif-copaxone-and-tysabri-for-active-multiple-sclerosis-107394https://curecurrent.com/trials/betaferon-regulatory-post-marketing-surveillance-107395https://curecurrent.com/trials/a-study-to-evaluate-the-pharmacokinetic-profiles-of-single-14-mg-teriflunomide-tablet-in-healthy-chinese-volunteers-107396https://curecurrent.com/trials/post-marketing-surveillance-study-to-evaluate-the-tolerability-of-rebif-new-formulation-in-patients-with-relapsing-multi-107397https://curecurrent.com/trials/pregnancy-exposure-registry-for-tysabri-107398https://curecurrent.com/trials/evaluation-of-patient-reported-outcomes-in-rrms-patients-candidates-for-ms-therapy-change-and-transitioned-to-fingolimod-107399https://curecurrent.com/trials/disease-control-and-safety-in-patients-with-relapsing-remitting-multiple-sclerosis-rrms-switching-from-natalizumab-to-fi-107400https://curecurrent.com/trials/rebif-compliance-support-program-assessing-needs-in-multiple-sclerosis-107401https://curecurrent.com/trials/to-identify-and-evaluate-the-predictive-factors-for-depression-in-patients-diagnosed-with-multiple-sclerosis-107402https://curecurrent.com/trials/a-retrospective-study-to-understand-the-clinical-management-of-subjects-with-multiple-sclerosis-at-a-site-in-taiwan-over-107403https://curecurrent.com/trials/pharmacogenetic-trial-and-long-term-follow-up-of-the-prisms-trial-prisms-15-107404https://curecurrent.com/trials/safety-tolerability-and-adherence-with-rebif-new-formulation-in-real-life-settings-star-107405https://curecurrent.com/trials/use-of-two-deep-brain-stimulation-dbs-electrodes-to-treat-post-traumatic-tremor-107406https://curecurrent.com/trials/mobility-enhancing-nursing-intervention-107407https://curecurrent.com/trials/neuropsychological-profile-of-a-patient-s-group-with-multiple-sclerosis-and-effect-of-a-cognitive-rehabilitation-program-107408https://curecurrent.com/trials/an-observational-study-for-the-assessment-of-compliance-and-persistence-to-rebif-therapy-of-patients-with-relapsing-remi-107409https://curecurrent.com/trials/a-scandinavian-non-interventional-study-of-adherence-to-rebismart-administered-rebif-new-formulation-rnf-treatment-in-re-107410https://curecurrent.com/trials/an-observational-study-comparing-multiple-sclerosis-international-quality-of-life-questionnaire-musiqol-and-multiple-scl-107411https://curecurrent.com/trials/an-observational-study-evaluating-therapy-optimisation-using-high-frequency-and-high-dosage-administration-of-interferon-107412https://curecurrent.com/trials/an-observational-study-to-document-the-effectiveness-and-compatibility-of-rebif-44-or-22-g-in-the-therapy-of-the-chronic-107413https://curecurrent.com/trials/a-study-to-evaluate-rebif-new-formulation-interferon-beta-1a-in-relapsing-remitting-multiple-sclerosis-107414https://curecurrent.com/trials/treatment-adherence-when-using-rebismart-in-relapsing-multiple-sclerosis-subjects-107415https://curecurrent.com/trials/evaluation-of-brain-atrophy-in-cis-patients-on-avonex-107416https://curecurrent.com/trials/oral-testosterone-for-fatigue-in-male-multiple-sclerosis-patients-107417https://curecurrent.com/trials/open-label-extension-study-to-evaluate-the-safety-and-tolerability-of-oral-fampridine-sustained-release-sr-in-canadian-p-107418https://curecurrent.com/trials/a-proof-of-concept-study-to-evaluate-the-effectiveness-of-tysabri-in-relapsing-remitting-multiple-sclerosis-rrms-patient-107419https://curecurrent.com/trials/physical-disability-in-patients-treated-with-betaferon-107420https://curecurrent.com/trials/a-multi-center-multi-regional-observational-study-to-test-the-responsiveness-of-the-validated-musiqol-multiple-sclerosis-107421https://curecurrent.com/trials/dalfampridine-for-imbalance-in-multiple-sclerosis-107422https://curecurrent.com/trials/peginterferon-beta-1a-biib017-autoinjector-pharmacokinetic-study-in-healthy-volunteers-107423https://curecurrent.com/trials/pregnancy-exposure-registry-for-avonex-interferon-beta-1a-107424https://curecurrent.com/trials/efficacy-and-safety-of-teriflunomide-in-patients-with-relapsing-multiple-sclerosis-and-treated-with-interferon-beta-107425https://curecurrent.com/trials/trial-of-ginkgo-as-a-treatment-for-cognitive-problems-in-multiple-sclerosis-107426https://curecurrent.com/trials/fmri-study-of-treatment-recommendations-comparing-recently-diagnosed-multiple-sclerosis-ms-patients-to-controls-107427https://curecurrent.com/trials/evaluate-the-safe-and-effective-use-of-the-avonex-single-use-autoinjector-in-multiple-sclerosis-subjects-107428https://curecurrent.com/trials/optical-coherence-tomography-in-multiple-sclerosis-patients-107429https://curecurrent.com/trials/jc-virus-jcv-epidemiology-in-multiple-sclerosis-ms-107430https://curecurrent.com/trials/aspirin-for-treatment-of-multiple-sclerosis-related-fatigue-107431https://curecurrent.com/trials/safety-and-efficacy-of-natalizumab-bg00002-tysabri-in-russian-participants-with-relapsing-remitting-multiple-sclerosis-r-107432https://curecurrent.com/trials/natalizumab-high-titer-immunogenicity-and-safety-107433https://curecurrent.com/trials/effect-of-fingolimod-on-the-cardiac-autonomic-regulation-in-patients-with-multiple-sclerosis-107434https://curecurrent.com/trials/extension-of-prior-study-evaluating-safety-and-tolerability-of-two-doses-of-betaseron-to-treat-relapsing-remitting-multi-107435https://curecurrent.com/trials/immunogenicity-and-safety-of-subcutaneously-administered-avonex-interferon-beta-1a-in-multiple-sclerosis-ms-patients-107436https://curecurrent.com/trials/influence-of-high-intensity-exercise-on-insulin-resistance-muscle-contractile-properties-aerobic-capacity-and-body-compo-107437https://curecurrent.com/trials/stabilometric-assessment-of-balance-recovery-in-persons-with-multiple-sclerosis-107438https://curecurrent.com/trials/hematopoietic-stem-cell-therapy-for-patients-with-multiple-sclerosis-107439https://curecurrent.com/trials/natalizumab-de-escalation-with-interferon-beta-1b-107440https://curecurrent.com/trials/task-oriented-circuit-class-training-in-multiple-sclerosis-subjects-107441https://curecurrent.com/trials/neuroprotection-with-riluzole-patients-with-early-multiple-sclerosis-107442https://curecurrent.com/trials/effects-of-targeted-lower-extremity-joint-training-on-multiple-sclerosis-ms-gait-abnormalities-107443https://curecurrent.com/trials/assessment-of-the-pharmacokinetics-of-circadin-in-children-with-neurodevelopmental-disorders-and-sleep-disturbances-107444https://curecurrent.com/trials/long-term-prospective-study-evaluating-clinical-and-molecular-biomarkers-of-epileptogenesis-in-a-genetic-model-of-epilep-107445https://curecurrent.com/trials/effects-of-a-12-week-respiratory-muscles-training-program-in-persons-with-relapsing-remitting-multiple-sclerosis-107446https://curecurrent.com/trials/combination-therapy-in-patients-with-relapsing-remitting-multiple-sclerosis-ms-combirx-107447https://curecurrent.com/trials/evaluation-of-the-positron-emission-tomography-pet-tracer-zk-6032924-in-patients-with-multiple-sclerosis-compared-to-hea-107448https://curecurrent.com/trials/an-efficacy-safety-and-tolerability-study-of-glatiramer-acetate-ga-20-mg-0-5-ml-new-formulation-administered-daily-by-su-107449https://curecurrent.com/trials/core-stability-training-in-multiple-sclerosis-107450https://curecurrent.com/trials/a-postmarketing-surveillance-pms-study-to-evaluate-the-extent-to-which-patient-compliance-is-influenced-by-use-of-a-vari-107451https://curecurrent.com/trials/an-observational-study-of-multiple-sclerosis-ms-patients-starting-or-restarting-baseline-treatment-with-interferon-beta-107452https://curecurrent.com/trials/a-phase-iia-study-of-nt-ko-003-for-multiple-sclerosis-107453https://curecurrent.com/trials/a-canadian-study-assessing-the-utility-of-the-treatment-optimization-recommendations-in-multiple-sclerosis-107454https://curecurrent.com/trials/impact-of-vitamin-a-supplementation-on-immune-system-in-multiple-sclerosis-patients-107455https://curecurrent.com/trials/safety-and-neuroprotective-effects-of-polyphenon-e-in-ms-phase-ii-107456https://curecurrent.com/trials/study-of-alemtuzumab-in-treatment-refractory-ms-subjects-alemtuzumab-naive-alemtuzumab-experienced-subjects-107457https://curecurrent.com/trials/the-rebif-vs-glatiramer-acetate-in-relapsing-multiple-sclerosis-pharmacogenetics-trial-107458https://curecurrent.com/trials/autologous-t-cell-vaccine-tcv-for-multiple-sclerosis-107459https://curecurrent.com/trials/a-observational-prospective-study-to-assess-the-impact-of-fatigue-in-the-quality-of-life-of-patients-with-multiple-scler-107460https://curecurrent.com/trials/a-study-to-evaluate-rituximab-in-adults-with-relapsing-remitting-multiple-sclerosis-107461https://curecurrent.com/trials/transition-to-rebif-new-formulation-107462https://curecurrent.com/trials/a-phase-iv-study-of-rebif-44mcg-administered-three-times-per-week-by-subcutaneous-injection-compared-with-no-treatment-i-107463https://curecurrent.com/trials/study-to-evaluate-the-immunogenicity-and-safety-of-r-hifn-beta-1a-rebif-using-clone-484-39-in-multiple-sclerosis-107464https://curecurrent.com/trials/simvastatin-as-an-add-on-treatment-to-copaxone-for-the-treatment-of-relapsing-multiple-sclerosis-107465https://curecurrent.com/trials/tolerability-of-rebif-interferon-beta-1-a-therapy-in-korean-patients-with-multiple-sclerosis-107466https://curecurrent.com/trials/assessment-of-patient-use-of-a-new-device-rebismart-107467https://curecurrent.com/trials/an-observational-study-to-assess-the-quality-of-life-of-the-patients-with-multiple-sclerosis-and-their-caregivers-107468https://curecurrent.com/trials/mesenchymal-stem-cell-transplantation-in-ms-107469https://curecurrent.com/trials/hydroxyurea-in-primary-progressive-multiple-sclerosis-107470https://curecurrent.com/trials/a-6-month-randomized-open-label-patient-outcomes-safety-and-tolerability-study-of-fingolimod-fty720-0-5-mg-day-vs-compar-107471https://curecurrent.com/trials/a-safety-and-efficacy-study-of-oral-cladribine-in-subjects-with-relapsing-remitting-multiple-sclerosis-rrms-107472https://curecurrent.com/trials/an-observational-retrospective-uk-ireland-audit-of-patient-adherence-to-rebif-injections-using-the-rebismart-injection-d-107473https://curecurrent.com/trials/assessment-of-subject-use-of-the-rebiject-ii-injection-device-according-to-nurse-examination-of-subject-accuracy-in-10-s-107474https://curecurrent.com/trials/an-observational-study-to-evaluate-quality-of-life-qol-and-influence-of-cognitive-status-on-qol-in-patients-with-relapsi-107475https://curecurrent.com/trials/naps-ms-natalizumab-effects-on-parameters-of-sleep-in-patients-with-multiple-sclerosis-experiencing-fatigue-or-sleepines-107476https://curecurrent.com/trials/rebif-flexible-dosing-in-early-multiple-sclerosis-ms-107477https://curecurrent.com/trials/natalizumab-de-escalation-to-interferon-beta-1b-in-patients-with-relapsing-remitting-multiple-sclerosis-107478https://curecurrent.com/trials/comparison-of-bone-effects-with-copaxone-and-interferon-in-multiple-sclerosis-107479https://curecurrent.com/trials/neurophysiological-study-of-sativex-in-multiple-sclerosis-ms-spasticity-107480https://curecurrent.com/trials/robot-assisted-gait-training-in-multiple-sclerosis-subjects-107481https://curecurrent.com/trials/testing-the-efficacy-of-self-generation-treatment-protocol-107482https://curecurrent.com/trials/assessment-study-of-steroid-effect-in-relapsing-multiple-sclerosis-subjects-treated-with-glatiramer-acetate-107483https://curecurrent.com/trials/benefit-study-betaferon-betaseron-in-newly-emerging-multiple-sclerosis-for-initial-treatment-and-benefit-follow-up-study-107484https://curecurrent.com/trials/evaluation-of-emotional-disorders-during-treatment-by-interferon-beta-in-relapsing-remitting-multiple-sclerosis-patients-107485https://curecurrent.com/trials/minocycline-as-add-on-to-interferon-beta-1a-ifn-beta-1a-rebif-in-relapsing-remitting-multiple-sclerosis-rrms-107486https://curecurrent.com/trials/a-study-of-the-safety-and-efficacy-of-ono-4641-in-patients-with-relapsing-remitting-multiple-sclerosis-107487https://curecurrent.com/trials/development-and-evaluation-of-a-cognitive-rehabilitation-program-for-persons-with-multiple-sclerosis-107488https://curecurrent.com/trials/interest-of-dynamic-measures-of-the-pupil-in-optic-neuritis-107489https://curecurrent.com/trials/testing-mitochondria-activity-and-blood-lipid-content-of-multiple-sclerosis-patients-107490https://curecurrent.com/trials/zoledronic-acid-in-ms-patients-with-osteoporosis-107491https://curecurrent.com/trials/evaluation-of-angioplasty-in-the-treatment-of-chronic-cerebrospinal-venous-insufficiency-ccsvi-in-multiple-sclerosis-107492https://curecurrent.com/trials/high-dose-chemo-with-stem-cell-transplant-as-treatment-for-multiple-sclerosis-that-failed-prior-treatment-107493https://curecurrent.com/trials/immune-regulation-in-multiple-sclerosis-microrna-and-antigen-presenting-cells-107494https://curecurrent.com/trials/12-week-study-to-evaluate-rebismart-suitability-for-self-injection-in-relapsing-multiple-sclerosis-107495https://curecurrent.com/trials/prospective-open-label-tolerability-and-safety-monitoring-study-of-novantrone-in-a-selected-cohort-of-multiple-sclerosis-107496https://curecurrent.com/trials/bayer-cognitive-assessments-with-multiple-sclerosis-subjects-107497https://curecurrent.com/trials/determine-impact-of-multiple-nab-tests-on-treatment-compared-to-usual-care-of-ms-patients-on-high-dose-ifn-therapy-107498https://curecurrent.com/trials/sodium-intake-in-multiple-sclerosis-107499https://curecurrent.com/trials/safety-study-in-relapsing-remitting-multiple-sclerosis-rrms-patients-receiving-betaferon-or-rebif-107500https://curecurrent.com/trials/evaluation-of-two-glatiramer-acetate-ga-formulations-in-relapsing-remitting-multiple-sclerosis-rrms-patients-107501https://curecurrent.com/trials/to-assess-the-prevalence-of-spasticity-and-the-impact-on-the-quality-of-life-in-multiple-sclerosis-patients-107502https://curecurrent.com/trials/correlation-between-multiple-sclerosis-functional-composite-msfc-and-expanded-disability-status-scale-edss-in-patients-w-107503https://curecurrent.com/trials/sexual-dysfunction-disability-and-quality-of-life-in-patients-with-multiple-sclerosis-ms-107504https://curecurrent.com/trials/impact-of-armodafinil-on-neurocognition-and-cognitive-fatigue-in-multiple-sclerosis-ms-107505https://curecurrent.com/trials/an-open-label-proof-of-concept-study-to-evaluate-the-effects-of-dalfampridine-withdrawal-on-gait-and-balance-parameters-107506https://curecurrent.com/trials/anti-inflammatory-type-ii-monocyte-induction-by-glatiramer-acetate-copaxone-treatment-of-multiple-sclerosis-107507https://curecurrent.com/trials/modafinil-in-multiple-sclerosis-107508https://curecurrent.com/trials/rad001-therapy-of-angiomyolipomata-in-patients-with-ts-complex-and-sporadic-lam-107509https://curecurrent.com/trials/phase-3-study-to-evaluate-efficacy-and-safety-of-nu100-in-patients-with-relapsing-remitting-multiple-sclerosis-rrms-107510https://curecurrent.com/trials/lokomat-training-effects-on-ms-gait-abnormalities-107511https://curecurrent.com/trials/targeted-lower-extremity-joint-training-107512https://curecurrent.com/trials/restoration-of-walking-in-multiple-sclerosis-using-treadmill-training-107513https://curecurrent.com/trials/effect-of-robot-assisted-training-on-foot-drop-in-multiple-sclerosis-107514https://curecurrent.com/trials/treatment-interruption-of-natalizumab-107515https://curecurrent.com/trials/long-term-follow-up-for-rad001-therapy-of-angiomyolipomata-in-patients-with-tuberous-sclerosis-tsc-and-sporadic-lymphang-107516https://curecurrent.com/trials/an-observational-study-for-the-assessment-of-adherence-effectiveness-and-convenience-of-rebif-treatment-in-relapsing-mul-107517https://curecurrent.com/trials/avonex-safety-and-tolerability-in-chinese-subjects-with-relapsing-multiple-sclerosis-ms-107518https://curecurrent.com/trials/matrix-measuring-neutralizing-antibodies-in-the-patients-treated-with-interferon-beta-1a-im-in-mexico-and-colombia-107519https://curecurrent.com/trials/is-ifn-beta-treatment-in-ms-useful-after-a-washout-period-in-patients-with-neutralizing-antibodies-to-interferon-beta-107520https://curecurrent.com/trials/dose-escalation-study-to-evaluate-the-penetration-and-pharmacodynamic-effects-of-baminercept-in-the-cerebrospinal-fluid-107521https://curecurrent.com/trials/avonex-pen-satisfaction-and-patients-experience-clinical-trial-107522https://curecurrent.com/trials/avonex-interferon-beta-1a-and-avonex-plus-methylprednisolone-for-the-treatment-of-relapsing-remitting-ms-107523https://curecurrent.com/trials/stress-management-for-patients-with-multiple-sclerosis-107524https://curecurrent.com/trials/post-authorization-observational-study-to-evaluate-cognition-and-fatigue-in-relapsing-remitting-multiple-sclerosis-rrms-107525https://curecurrent.com/trials/study-of-fampridine-er-tablets-in-patients-with-multiple-sclerosis-107526https://curecurrent.com/trials/an-extension-study-of-the-efficacy-and-safety-of-fingolimod-fty720-in-patients-with-relapsing-multiple-sclerosis-107527https://curecurrent.com/trials/telephone-intervention-for-pain-study-tips-107528https://curecurrent.com/trials/a-multicenter-open-label-randomized-crossover-trial-to-assess-subject-preference-for-kemstro-compared-to-conventional-ba-107529https://curecurrent.com/trials/a-multinational-randomized-double-blind-parallel-group-placebo-controlled-study-assessing-the-safety-and-tolerability-107530https://curecurrent.com/trials/the-efficacy-of-vitamin-k2-n-human-osteoporosis-blood-vessel-calcification-and-sclerosis-107531https://curecurrent.com/trials/validation-of-hand-held-dynamometer-for-assessment-of-lower-limb-muscle-strength-in-multiple-sclerosis-107532https://curecurrent.com/trials/a-multicenter-open-label-rebismart-autoinjector-ease-of-use-study-107533https://curecurrent.com/trials/effect-of-i-travle-training-on-arm-function-in-ms-and-chronic-stroke-patients-107534https://curecurrent.com/trials/rebif-new-formulation-rnf-quality-of-life-qol-study-107535https://curecurrent.com/trials/rnf-and-betaseron-tolerability-study-107536https://curecurrent.com/trials/the-multicenter-open-label-single-use-autoinjector-convenience-study-107537https://curecurrent.com/trials/implementation-study-of-treatment-optimization-recommendations-on-relapsing-remitting-multiple-sclerosis-rr-ms-subjects-107538https://curecurrent.com/trials/tolerability-of-rebif-injection-with-and-without-the-use-of-rebiject-mini-in-relapsing-remitting-multiple-sclerosis-subj-107539https://curecurrent.com/trials/rebif-pregnancy-registry-107540https://curecurrent.com/trials/a-study-of-rebif-compared-with-avonex-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-ms-107541https://curecurrent.com/trials/a-phase-ii-study-of-orally-administered-bez235-monotherapy-in-patients-with-metastatic-or-unresectable-malignant-pecoma-107542https://curecurrent.com/trials/comprehensive-analysis-of-relapse-in-multiple-sclerosis-107543https://curecurrent.com/trials/exercise-in-severely-disabled-patients-with-ms-107544https://curecurrent.com/trials/cyclic-oral-methylprednisolone-trial-in-multiple-sclerosis-107545https://curecurrent.com/trials/safety-of-polyphenon-e-in-multiple-sclerosis-pilot-study-107546https://curecurrent.com/trials/evaluation-of-risk-factors-for-early-termination-of-injection-treatment-with-betaferon-in-patients-suffering-from-multip-107547https://curecurrent.com/trials/sativex-versus-placebo-when-added-to-existing-treatment-for-central-neuropathic-pain-in-ms-107548https://curecurrent.com/trials/longitudinal-weekly-follow-up-of-active-plaques-in-multiple-sclerosis-with-3-teslas-multi-modality-mri-using-diffusion-p-107549https://curecurrent.com/trials/safety-and-efficacy-of-cellcept-and-avonex-as-combination-treatment-in-multiple-sclerosis-107550https://curecurrent.com/trials/analysis-of-lymphocyte-cell-surface-adhesion-marker-expression-in-natalizumab-population-with-active-control-107551https://curecurrent.com/trials/improving-new-learning-and-memory-in-multiple-sclerosis-107552https://curecurrent.com/trials/functional-and-physiological-responses-to-lokomat-therapy-pilot-study-107553https://curecurrent.com/trials/the-effect-of-anodal-tdcs-on-motor-learning-in-multiple-sclerosis-107554https://curecurrent.com/trials/avonex-safety-blood-levels-and-effects-107555https://curecurrent.com/trials/efficacy-of-fish-oil-in-multiple-sclerosis-107556https://curecurrent.com/trials/investigation-of-gm-pathology-using-ultra-high-field-7t-mri-scanner-107557https://curecurrent.com/trials/mesenchymal-stem-cells-for-multiple-sclerosis-107558https://curecurrent.com/trials/occupational-therapy-in-patients-with-multiple-sclerosis-107559https://curecurrent.com/trials/a-longitudinal-study-of-brain-atrophy-in-ms-patients-over-5-years-107560https://curecurrent.com/trials/whole-body-vibration-therapy-in-participants-with-ms-related-balance-deficits-107561https://curecurrent.com/trials/safety-study-of-combination-therapy-with-intramuscular-avonex-and-oral-cellcept-in-patients-with-multiple-sclerosis-107562https://curecurrent.com/trials/modeling-and-treating-the-pathophysiology-of-demyelination-in-multiple-sclerosis-107563https://curecurrent.com/trials/continuous-positive-airway-pressure-cpap-for-fatigue-in-patients-with-multiple-sclerosis-ms-and-obstructive-sleep-apnea-107564https://curecurrent.com/trials/a-longitudinal-study-of-effect-of-copaxone-in-rrms-over-24-months-107565https://curecurrent.com/trials/the-effects-of-attention-retraining-in-ms-107566https://curecurrent.com/trials/teleconference-fatigue-management-for-people-with-multiple-sclerosis-107567https://curecurrent.com/trials/study-evaluating-cci-779-in-relapsing-multiple-sclerosis-107568https://curecurrent.com/trials/safety-and-immunologic-effect-of-low-dose-versus-high-dose-vitamin-d3-in-multiple-sclerosis-107569https://curecurrent.com/trials/therapy-optimization-in-multiple-sclerosis-ms-107570https://curecurrent.com/trials/effects-of-vestibular-rehabilitation-on-ms-related-fatigue-a-randomized-control-trial-107571https://curecurrent.com/trials/neuroprotection-and-repair-in-optic-neuritis-107572https://curecurrent.com/trials/management-of-pain-in-persons-with-multiple-sclerosis-107573https://curecurrent.com/trials/vitamine-d-in-multiple-sclerosis-107574https://curecurrent.com/trials/safety-and-effectiveness-of-two-doses-of-abt-874-as-compared-to-placebo-in-subjects-with-multiple-sclerosis-ms-107575https://curecurrent.com/trials/study-of-teriflunomide-in-reducing-the-frequency-of-relapses-and-accumulation-of-disability-in-patients-with-multiple-sc-107576https://curecurrent.com/trials/long-term-safety-of-teriflunomide-when-added-to-interferon-beta-or-glatiramer-acetate-in-patients-with-multiple-sclerosi-107577https://curecurrent.com/trials/role-of-vitamin-d-in-reducing-the-relapse-rate-in-patients-with-multiple-sclerosis-107578https://curecurrent.com/trials/safety-study-of-an-immunomodulating-microparticle-to-treat-progressive-multiple-sclerosis-107579https://curecurrent.com/trials/the-efficacy-of-emdr-in-patients-with-ptsd-in-multiple-sclerosis-107580https://curecurrent.com/trials/efficacy-and-safety-of-methylprednisolone-per-os-versus-iv-for-the-treatment-of-multiple-sclerosis-ms-relapses-107581https://curecurrent.com/trials/randomized-controlled-trial-to-test-the-efficacy-of-interferon-beta-in-the-treatment-of-intermediate-uveitis-107582https://curecurrent.com/trials/response-to-interferon-alpha-in-interferon-neutralizing-antibody-positive-multiple-sclerosis-patients-107583https://curecurrent.com/trials/safety-and-efficacy-of-umbilical-cord-mesenchymal-stem-cell-therapy-for-patients-with-progressive-multiple-sclerosis-and-107584https://curecurrent.com/trials/betaseron-16-year-long-term-follow-up-ltf-in-patients-with-relapsing-remitting-multiple-sclerosis-107585https://curecurrent.com/trials/demonstrate-the-bioequivalence-of-interferon-beta-1a-infb-manufactured-by-two-different-processes-in-healthy-volunteers-107586https://curecurrent.com/trials/betaplus-survey-observational-study-to-assess-drug-adherence-in-patients-with-multiple-sclerosis-after-conversion-to-bet-107587https://curecurrent.com/trials/combination-therapy-using-cellcept-and-rebif-in-rrms-107588https://curecurrent.com/trials/magnetic-resonance-imaging-mri-follow-up-of-macrophagic-infiltration-in-ms-patients-treated-with-tysabri-107589https://curecurrent.com/trials/a-study-of-the-pharmacokinetics-and-immunologic-effects-of-lipoic-acid-in-multiple-sclerosis-107590https://curecurrent.com/trials/phase-ii-study-of-teriflunomide-as-adjunctive-therapy-to-interferon-beta-in-subjects-with-multiple-sclerosis-107591https://curecurrent.com/trials/phase-ii-study-of-teriflunomide-as-adjunctive-therapy-to-glatiramer-acetate-in-subjects-with-multiple-sclerosis-107592https://curecurrent.com/trials/portuguese-observational-survey-to-assess-drug-adherence-in-patients-with-multiple-sclerosis-after-conversion-to-betafer-107593https://curecurrent.com/trials/effect-of-melatonin-on-multiple-sclerosis-related-fatigue-107594https://curecurrent.com/trials/ginseng-in-treatment-of-fatigue-in-multiple-sclerosis-107595https://curecurrent.com/trials/impact-of-vitamin-a-on-rar-gene-expression-in-multiple-sclerosis-107596https://curecurrent.com/trials/safety-and-efficacy-of-teriflunomide-hmr1726-in-multiple-sclerosis-with-relapses-107597https://curecurrent.com/trials/safety-and-efficacy-study-of-erythropoietin-as-add-on-therapy-of-methylprednisolone-to-treat-acute-optic-neuritis-107598https://curecurrent.com/trials/motor-training-and-white-matter-in-multiple-sclerosis-ms-107599https://curecurrent.com/trials/long-term-study-of-fingolimod-in-ms-patients-from-the-fty-clinical-program-107600https://curecurrent.com/trials/the-effect-of-transcutaneous-electrical-nerve-stimulation-tens-in-multiple-sclerosis-107601https://curecurrent.com/trials/the-effects-of-interferon-beta-combined-with-vitamin-d-on-relapsing-remitting-multiple-sclerosis-patients-107602https://curecurrent.com/trials/study-on-cognitive-disorders-of-multiple-sclerosis-107603https://curecurrent.com/trials/efficacy-and-safety-of-fingolimod-fty720-in-patients-with-relapsing-remitting-multiple-sclerosis-107604https://curecurrent.com/trials/controlled-high-risk-avonex-multiple-sclerosis-prevention-study-in-ongoing-neurological-surveillance-107605https://curecurrent.com/trials/early-cognitive-impairment-in-multiple-sclerosis-107606https://curecurrent.com/trials/experimental-evaluation-of-wheelchair-mounted-robotic-arms-107607https://curecurrent.com/trials/efficacy-and-safety-evaluation-of-nabilone-as-adjunctive-therapy-to-gabapentin-for-the-management-of-neuropathic-pain-in-107608https://curecurrent.com/trials/neuropathic-pain-assessment-comparing-pregabalin-and-paroxetine-in-management-of-ms-induced-neuropathic-pain-107609https://curecurrent.com/trials/impact-of-vitamin-a-on-gene-expression-in-multiple-sclerosis-patient-107610https://curecurrent.com/trials/long-term-efficacy-and-safety-of-fingolimod-fty720-in-patients-with-relapsing-remitting-multiple-sclerosis-107611https://curecurrent.com/trials/evaluate-early-glatiramer-acetate-treatment-in-delaying-conversion-to-clinically-definite-multiple-sclerosis-of-subjects-107612https://curecurrent.com/trials/effect-of-treatment-with-fingolimod-on-the-immune-response-following-seasonal-flu-vaccination-and-tetanus-booster-inject-107613https://curecurrent.com/trials/the-role-of-serum-leptin-levels-in-multiple-sclerosis-disease-activity-while-on-interferon-beta-1a-rebif-treatment-107614https://curecurrent.com/trials/a-randomized-exercise-trial-for-wheelchair-users-107615https://curecurrent.com/trials/immunoregulation-by-controlled-parasite-exposure-in-multiple-sclerosis-107616https://curecurrent.com/trials/placebo-controlled-study-of-ono2506po-in-the-presence-of-riluzole-in-patients-with-amyotrophic-lateral-sclerosis-als-107617https://curecurrent.com/trials/a-phase-ii-multi-centre-extension-study-to-investigate-the-long-term-safety-of-ono-2506po-in-patients-diagnosed-with-amy-107618https://curecurrent.com/trials/memantine-therapy-for-multiple-sclerosis-107619https://curecurrent.com/trials/physical-activity-and-fatigue-in-early-multiple-sclerosis-ms-107620https://curecurrent.com/trials/cranberry-for-prevention-of-urinary-tract-infections-in-multiple-sclerosis-patients-107621https://curecurrent.com/trials/safety-and-efficacy-study-of-copaxone-administered-in-combination-with-n-acetylcysteine-107622https://curecurrent.com/trials/cognitive-testing-for-the-pain-quality-assessment-scale-pqas-107623https://curecurrent.com/trials/psychometric-validation-of-cognitive-endpoints-107624https://curecurrent.com/trials/a-safety-and-efficacy-study-of-cnto1275-in-patients-with-multiple-sclerosis-107625https://curecurrent.com/trials/qolbet-quality-of-life-in-patients-with-early-relapsing-remitting-multiple-sclerosis-treated-with-betaferon-in-korea-107626https://curecurrent.com/trials/efficacy-and-safety-of-fingolimod-in-patients-with-relapsing-remitting-multiple-sclerosis-107627https://curecurrent.com/trials/study-of-sb-683699-compared-to-placebo-in-subjects-with-relapsing-remitting-multiple-sclerosis-ms-107628https://curecurrent.com/trials/cognitive-effects-of-immunomodulatory-drugs-in-ms-107629https://curecurrent.com/trials/sensori-motor-integration-training-in-multiple-sclerosis-107630https://curecurrent.com/trials/efficacy-of-cyclophosphamide-versus-methylprednisolone-in-patients-with-secondary-progressive-multiple-sclerosis-107631https://curecurrent.com/trials/rivastigmine-in-multiple-sclerosis-patients-with-cognitive-impairment-107632https://curecurrent.com/trials/study-to-evaluate-treating-chronic-cerebrospinal-venous-insufficiency-ccsvi-in-multiple-sclerosis-patients-107633https://curecurrent.com/trials/herbal-therapy-for-subcutaneous-injection-site-reactions-in-multiple-sclerosis-107634https://curecurrent.com/trials/a-prospective-study-of-spasticity-in-individuals-with-multiple-sclerosis-107635https://curecurrent.com/trials/benefit-extension-study-107636https://curecurrent.com/trials/open-label-extension-study-to-evaluate-the-safety-tolerability-and-activity-of-oral-fampridine-sr-in-patients-with-multi-107637https://curecurrent.com/trials/pharmacokinetic-immunological-and-biochemical-sample-collection-and-analysis-of-a-tysabri-patient-cohort-107638https://curecurrent.com/trials/open-label-extension-study-to-evaluate-the-safety-tolerability-and-activity-of-oral-fampridine-sr-in-patients-with-multi-107639https://curecurrent.com/trials/topical-rapamycin-therapy-to-alleviate-cutaneous-manifestations-of-tuberous-sclerosis-complex-tsc-and-neurofibromatosis-107640https://curecurrent.com/trials/open-label-extension-study-to-evaluate-the-safety-tolerability-and-activity-of-oral-fampridine-sr-tablets-in-multiple-sc-107641https://curecurrent.com/trials/natalizumab-treatment-of-progressive-multiple-sclerosis-107642https://curecurrent.com/trials/efficacy-and-safety-of-the-pain-relieving-effect-of-dronabinol-in-central-neuropathic-pain-related-to-multiple-sclerosis-107643https://curecurrent.com/trials/compliance-with-avonex-ps-in-patients-with-relapsing-remitting-ms-107644https://curecurrent.com/trials/american-ginseng-treatment-for-multiple-sclerosis-related-fatigue-107645https://curecurrent.com/trials/longitudinal-pharmacokinetic-pharmacodynamic-immunological-and-biochemical-107646https://curecurrent.com/trials/telephone-interview-of-patients-that-participated-in-the-the-pivotal-betaferon-ms-trial-107647https://curecurrent.com/trials/popart-mus-prevention-of-post-partum-relapses-with-progestin-and-estradiol-in-multiple-sclerosis-107648https://curecurrent.com/trials/duloxetine-for-multiple-sclerosis-pain-107649https://curecurrent.com/trials/trichuris-suis-ova-therapy-for-relapsing-multiple-sclerosis-a-safety-study-107650https://curecurrent.com/trials/mesenchymal-stem-cells-in-multiple-sclerosis-mscims-107651https://curecurrent.com/trials/the-effects-of-aerobics-training-on-balance-in-patients-with-multiple-sclerosis-107652https://curecurrent.com/trials/clinical-trial-comparing-treatment-of-relapsing-remitting-multiple-sclerosis-rr-ms-with-two-doses-of-glatiramer-acetate-107653https://curecurrent.com/trials/t-cell-vaccination-in-patients-with-progressive-multiple-sclerosis-107654https://curecurrent.com/trials/cytotron-delivered-rotational-field-quantum-nuclear-magnetic-resonance-therapy-for-multiple-sclerosis-107655https://curecurrent.com/trials/colecalciferol-as-an-add-on-treatment-to-subcutaneously-administered-interferon-beta-1b-for-treatment-of-multiple-sclero-107656https://curecurrent.com/trials/cdp323-biomarker-study-107657https://curecurrent.com/trials/placebo-controlled-study-in-subjects-with-relapsing-forms-of-ms-to-evaluate-the-safety-tolerability-and-effects-of-cdp32-107658https://curecurrent.com/trials/efficacy-safety-and-tolerability-of-atorvastatin-40-mg-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-w-107659https://curecurrent.com/trials/effect-of-tysabri-in-patients-with-relapsing-remitting-multiple-sclerosis-a-follow-up-magnetization-transfer-imaging-mti-107660https://curecurrent.com/trials/can-vitamin-d-supplementation-prevent-bone-loss-in-persons-with-multiple-sclerosis-107661https://curecurrent.com/trials/aimspro-in-the-treatment-of-bladder-dysfunction-in-secondary-progressive-multiple-sclerosis-107662https://curecurrent.com/trials/impact-of-vitamin-a-on-multiple-sclerosis-ms-107663https://curecurrent.com/trials/study-of-alternative-exercise-therapies-for-progressive-multiple-sclerosis-ms-107664https://curecurrent.com/trials/health-behavior-change-in-chronic-disease-management-107665https://curecurrent.com/trials/the-effects-of-erythropoietin-on-clinical-disability-and-brain-pathology-in-patients-with-progressive-multiple-sclerosis-107666https://curecurrent.com/trials/zenapax-to-treat-multiple-sclerosis-107667https://curecurrent.com/trials/safety-and-efficacy-study-of-oral-fampridine-sr-in-patients-with-multiple-sclerosis-107668https://curecurrent.com/trials/safety-effectiveness-of-adding-monthly-dexamethasone-to-weekly-avonex-for-ms-107669https://curecurrent.com/trials/alfuzosin-for-voiding-dysfunction-in-multiple-sclerosis-ms-107670https://curecurrent.com/trials/cohort-study-of-clinically-isolated-syndrome-and-early-multiple-sclerosis-107671https://curecurrent.com/trials/oral-corticotherapy-in-megadoses-to-treat-multiple-sclerosis-during-relapse-107672https://curecurrent.com/trials/colecalciferol-as-an-add-on-treatment-to-interferon-beta-1b-for-treatment-of-multiple-sclerosis-ms-107673https://curecurrent.com/trials/efficacy-of-anti-tubercular-vaccination-in-multiple-sclerosis-107674https://curecurrent.com/trials/ambulation-study-in-multiple-sclerosis-107675https://curecurrent.com/trials/evaluating-alemtuzumab-as-a-treatment-in-stabilizing-neurocognitive-function-in-relapsing-remitting-multiple-sclerosis-p-107676https://curecurrent.com/trials/efficacy-and-safety-of-fty720-in-patients-with-relapsing-multiple-sclerosis-ms-107677https://curecurrent.com/trials/supported-treadmill-training-for-progressive-multiple-sclerosis-107678https://curecurrent.com/trials/a-study-to-evaluate-the-safety-and-effectiveness-of-novantrone-therapy-followed-by-copaxone-for-multiple-sclerosis-107679https://curecurrent.com/trials/a-study-to-evaluate-readiness-to-self-inject-on-adherence-and-compliance-to-copaxone-therapy-107680https://curecurrent.com/trials/safety-and-efficacy-study-of-copaxone-administered-in-combination-with-minocycline-107681https://curecurrent.com/trials/a-study-comparing-shared-solutions-plus-ms-center-support-versus-shared-solutions-alone-107682https://curecurrent.com/trials/a-study-to-evaluate-the-impact-on-skin-injection-site-reactions-of-taking-an-antihistamine-zyrtec-or-placebo-prior-to-da-107683https://curecurrent.com/trials/the-effectiveness-of-locomotor-therapy-using-robot-driven-gait-orthosis-system-in-multiple-sclerosis-patients-107684https://curecurrent.com/trials/a-study-to-evaluate-the-effectiveness-tolerability-and-safety-of-laquinimod-107685https://curecurrent.com/trials/a-study-to-evaluate-the-impact-on-skin-injection-site-reactions-of-using-alcohol-wipes-prior-to-daily-injections-of-copa-107686https://curecurrent.com/trials/success-of-titration-analgesics-and-b-e-t-a-nurse-support-on-acceptance-rates-in-early-multiple-sclerosis-ms-treatment-w-107687https://curecurrent.com/trials/biomarkers-and-response-to-natalizumab-for-multiple-sclerosis-treatment-107688https://curecurrent.com/trials/12-week-safety-evaluation-of-oral-cs-0777-in-multiple-sclerosis-patients-107689https://curecurrent.com/trials/efficacy-of-3-4-dap-in-fatigue-associated-with-multiple-sclerosis-107690https://curecurrent.com/trials/simvastatin-treatment-of-patients-with-acute-optic-neuritis-107691https://curecurrent.com/trials/a-study-to-evaluate-the-preliminary-efficacy-pharmacokinetics-and-immunogenicity-of-bms-188667-administered-to-subjects-107692https://curecurrent.com/trials/study-comparing-corpus-callosum-atrophy-as-a-marker-of-later-development-of-cognitive-impairment-in-patients-with-multip-107693https://curecurrent.com/trials/neurocognitive-changes-in-patients-with-remitting-relapsing-multiple-sclerosis-treated-with-natalizumab-107694https://curecurrent.com/trials/randomized-study-designed-to-look-at-disease-progression-using-2-currently-fda-approved-drugs-for-the-treatment-of-rrms-107695https://curecurrent.com/trials/simvastatin-as-an-add-on-treatment-to-interferon-beta-1a-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-107696https://curecurrent.com/trials/visual-impairment-oscillopsia-and-multiple-sclerosis-107697https://curecurrent.com/trials/study-of-the-safety-and-efficacy-of-mln1202-in-patients-in-multiple-sclerosis-107698https://curecurrent.com/trials/a-study-for-patients-with-relapsing-remitting-multiple-sclerosis-107699https://curecurrent.com/trials/a-study-for-patients-with-multiple-sclerosis-107700https://curecurrent.com/trials/vitamin-d3-supplementation-and-the-t-cell-compartment-in-multiple-sclerosis-ms-107701https://curecurrent.com/trials/simvastatin-in-relapsing-remitting-multiple-sclerosis-rrms-patients-using-avonex-compared-to-placebo-107702https://curecurrent.com/trials/efficacy-and-safety-study-of-gb-0998-for-treatment-of-systemic-sclerosis-107703https://curecurrent.com/trials/novel-immune-markers-in-patients-with-multiple-sclerosis-107704https://curecurrent.com/trials/real-world-betaseron-health-economic-outcomes-study-for-relapsing-forms-of-multiple-sclerosis-107705https://curecurrent.com/trials/open-lable-extension-study-on-safety-and-efficacy-of-neramexane-to-treat-congenital-and-acquired-nystagmus-107706https://curecurrent.com/trials/evaluation-of-neural-loss-in-multiple-sclerosis-and-neuromyelitis-optica-using-high-resolution-oct-107707https://curecurrent.com/trials/validation-of-an-obstacle-course-used-in-patients-with-muscle-tightness-107708https://curecurrent.com/trials/nasal-administration-of-dexamethasone-for-multiple-sclerosis-ms-treatment-107709https://curecurrent.com/trials/a-study-for-patients-with-secondary-progressive-multiple-sclerosis-107710https://curecurrent.com/trials/a-study-to-evaluate-the-long-term-safety-and-effectiveness-of-novantrone-therapy-followed-by-copaxone-treatment-for-mult-107711https://curecurrent.com/trials/intravesical-injection-of-botulinum-toxin-a-versus-saline-for-neurogenic-detrusor-overactivity-107712https://curecurrent.com/trials/avonex-15-year-long-term-follow-up-study-107713https://curecurrent.com/trials/atp-expression-in-lymphocytes-of-ms-patients-by-means-of-immuknow-assay-107714https://curecurrent.com/trials/optical-coherence-tomography-glatiramer-in-clinically-isolated-syndrome-or-early-relapsing-remitting-multiple-sclerosis-107715https://curecurrent.com/trials/a-randomised-controlled-trial-of-neuroprotection-with-lamotrigine-in-secondary-progressive-multiple-sclerosis-107716https://curecurrent.com/trials/climate-influence-on-physiotherapy-in-multiple-sclerosis-107717https://curecurrent.com/trials/study-to-determine-if-avonex-and-rebif-work-comparably-well-in-subjects-with-relapsing-multiple-sclerosis-107718https://curecurrent.com/trials/a-study-to-test-the-effectiveness-and-safety-of-a-new-higher-40mg-dose-of-copaxone-compared-to-copaxone-20mg-the-current-107719https://curecurrent.com/trials/levetiracetam-in-central-pain-in-multiple-sclerosis-ms-107720https://curecurrent.com/trials/focus-fatigue-outcome-in-copaxone-users-107721https://curecurrent.com/trials/exploratory-study-to-investigate-the-reparative-and-regenerative-potential-of-alemtuzumab-in-relapsing-remitting-multipl-107722https://curecurrent.com/trials/beyond-pilot-study-107723https://curecurrent.com/trials/characteristic-study-on-chinese-patients-with-multiple-sclerosis-107724https://curecurrent.com/trials/a-multicenter-study-to-assess-the-effect-of-plasma-exchange-in-accelerating-the-clearance-of-natalizumab-in-subjects-wit-107725https://curecurrent.com/trials/efficacy-and-safety-of-mbp8298-in-subjects-with-secondary-progressive-multiple-sclerosis-107726https://curecurrent.com/trials/phase-ii-high-dose-cyclophosphamide-for-multiple-sclerosis-107727https://curecurrent.com/trials/atorvastatin-40-mg-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-interferon-beta-1b-107728https://curecurrent.com/trials/early-ifnb-1a-and-atorvastatin-combination-therapy-of-isolated-clinical-syndrome-suggestive-of-multiple-sclerosis-107729https://curecurrent.com/trials/open-label-natalizumab-safety-extension-study-107730https://curecurrent.com/trials/safety-and-efficacy-of-natalizumab-in-combination-with-avonex-in-the-treatment-of-multiple-sclerosis-107731https://curecurrent.com/trials/natalizumab-in-combination-with-glatiramer-acetate-ga-in-patients-with-relapsing-remitting-multiple-sclerosis-107732https://curecurrent.com/trials/ger-009-06-avx-early-therapy-in-multiple-sclerosis-107733https://curecurrent.com/trials/development-and-evaluation-of-a-new-palliative-care-service-for-people-severely-affected-with-multiple-sclerosis-ms-107734https://curecurrent.com/trials/immunogenicity-and-safety-study-of-serum-free-avonex-107735https://curecurrent.com/trials/the-neuroprotective-effect-of-lamotrigine-and-interferon-beta-1a-in-patients-with-relapsing-remitting-multiple-sclerosis-107736https://curecurrent.com/trials/open-label-safety-extension-study-of-avonex-107737https://curecurrent.com/trials/patient-satisfaction-study-of-single-use-autoinjector-for-the-delivery-of-pre-filled-avonex-syringe-107738https://curecurrent.com/trials/comparison-of-campath-and-rebif-treatment-on-cognition-in-multiple-sclerosis-ms-107739https://curecurrent.com/trials/pharmacodynamic-study-to-better-understand-the-therapeutic-response-and-immunomodulatory-effects-of-avonex-in-multiple-s-107740https://curecurrent.com/trials/a-bioequivalence-study-of-serum-free-avonex-and-serum-containing-avonex-in-healthy-volunteers-107741https://curecurrent.com/trials/motor-imagery-practice-in-neurological-rehabilitation-107742https://curecurrent.com/trials/motor-point-stimulation-for-conditioning-the-diaphragm-of-patients-with-amyotrophic-lateral-sclerosis-als-107743https://curecurrent.com/trials/diagnostic-study-of-quantitative-imaging-and-spectroscopy-in-patients-with-multiple-sclerosis-107744https://curecurrent.com/trials/differential-immune-effects-of-natalizumab-107745https://curecurrent.com/trials/safety-study-of-rtl1000-recombinant-t-cell-receptor-ligand-in-subjects-with-multiple-sclerosis-107746https://curecurrent.com/trials/one-year-extension-study-to-protocol-c2-5-tz-ms-05-107747https://curecurrent.com/trials/study-of-nighttime-dosing-of-sublingual-tizanidine-12-mg-in-multiple-sclerosis-ms-patients-with-significant-spasticity-107748https://curecurrent.com/trials/far-infrared-irradiation-for-managing-and-treating-multiple-sclerosis-ms-107749https://curecurrent.com/trials/eszopiclone-for-improving-sleep-in-multiple-sclerosis-ms-107750https://curecurrent.com/trials/beyond-betaferon-betaseron-efficacy-yielding-outcomes-of-a-new-dose-in-multiple-sclerosis-ms-patients-107751https://curecurrent.com/trials/tolerability-and-bioavailability-of-the-p144-peptide-inhibitor-of-tgf-1-after-topical-administration-in-healthy-voluntee-107752https://curecurrent.com/trials/safety-and-preliminary-effectiveness-of-av650-in-patients-with-spasticity-associated-with-multiple-sclerosis-107753https://curecurrent.com/trials/whole-body-vibration-therapy-in-a-participant-with-multiple-sclerosis-related-balance-deficits-a-case-study-107754https://curecurrent.com/trials/phase-iii-randomized-double-blind-placebo-controlled-study-of-intravenous-immune-globulin-for-multiple-sclerosis-107755https://curecurrent.com/trials/how-side-effects-of-avonex-are-affected-by-gradually-increasing-to-full-dose-vs-starting-at-full-dose-107756https://curecurrent.com/trials/multiple-sclerosis-and-heavy-progressive-resistance-training-107757https://curecurrent.com/trials/study-of-subcutaneous-daclizumab-in-patients-with-active-relapsing-forms-of-multiple-sclerosis-107758https://curecurrent.com/trials/constraint-induced-ci-movement-therapy-for-progressive-multiple-sclerosis-ms-107759https://curecurrent.com/trials/auditory-function-in-patients-with-and-without-multiple-sclerosis-107760https://curecurrent.com/trials/a-study-of-c105-on-cognitive-dysfunction-in-persons-with-multiple-sclerosis-107761https://curecurrent.com/trials/a-randomized-placebo-controlled-crossover-design-study-of-the-effects-of-low-dose-naltrexone-107762https://curecurrent.com/trials/avonex-combination-trial-act-107763https://curecurrent.com/trials/trial-of-efficacy-and-safety-of-sirolimus-in-tuberous-sclerosis-and-lam-107764https://curecurrent.com/trials/immunotherapy-with-bht-3009-alone-or-combined-with-atorvastatin-in-patients-with-multiple-sclerosis-107765https://curecurrent.com/trials/safety-trial-of-high-dose-oral-vitamin-d3-with-calcium-in-multiple-sclerosis-107766https://curecurrent.com/trials/evaluation-of-an-altered-peptide-ligand-nbi-5788-in-patients-with-relapsing-multiple-sclerosis-ms-107767https://curecurrent.com/trials/early-ifnb-1a-and-simvastatin-combination-therapy-in-clinically-isolated-syndrome-suggestive-of-multiple-sclerosis-107768https://curecurrent.com/trials/a-48-week-24-week-baseline-followed-by-a-24-week-treatment-phase-ii-pilot-study-of-the-tolerability-and-effect-efficacy-107769https://curecurrent.com/trials/safety-tolerability-and-effectiveness-of-cgp77116-in-patients-with-multiple-sclerosis-ms-107770https://curecurrent.com/trials/the-effect-of-sildenafil-citrate-viagra-registered-trademark-on-brain-blood-flow-in-multiple-sclerosis-patients-107771https://curecurrent.com/trials/rolipram-to-treat-multiple-sclerosis-107772https://curecurrent.com/trials/mr-perfusion-imaging-and-hypercapnia-increased-carbon-dioxide-to-study-new-blood-vessel-formation-in-multiple-sclerosis-107773https://curecurrent.com/trials/evaluation-of-the-efficacy-of-cesamet-for-the-treatment-of-pain-in-patients-with-multiple-sclerosis-107774https://curecurrent.com/trials/bht-3009-immunotherapy-in-relapsing-remitting-multiple-sclerosis-107775https://curecurrent.com/trials/safety-of-avonex-treatment-in-multiple-sclerosis-patients-with-neutralizing-antibodies-to-interferon-beta-therapy-107776https://curecurrent.com/trials/investigating-if-interferon-beta-can-be-used-in-patients-with-ms-after-they-have-developed-neutralizing-antibodies-107777https://curecurrent.com/trials/study-evaluating-mitoxantrone-in-multiple-sclerosis-107778https://curecurrent.com/trials/a-serologic-study-to-correlate-beta-ifn-nab-titers-to-beta-ifn-induced-biomarker-response-in-patients-with-multiple-scle-107779https://curecurrent.com/trials/fatigue-in-multiple-sclerosis-evaluated-with-3-mri-and-transcranial-magnetic-stimulation-107780https://curecurrent.com/trials/does-quality-of-life-improve-in-multiple-sclerosis-patients-treated-with-interferon-beta-1a-107781https://curecurrent.com/trials/an-fmri-study-of-treatment-optimization-comparing-two-disease-modifying-therapies-used-to-treat-relapsing-remitting-mult-107782https://curecurrent.com/trials/a-fmri-functional-magnetic-resonance-imaging-research-study-to-learn-more-about-multiple-sclerosis-and-individuals-poten-107783https://curecurrent.com/trials/correlation-between-cognitive-functions-and-mri-in-multiple-sclerosis-107784https://curecurrent.com/trials/promoting-physical-activity-for-persons-with-multiple-sclerosis-107785https://curecurrent.com/trials/optimizing-ifn-beta-1b-dose-107786https://curecurrent.com/trials/rapamycin-therapy-for-patients-with-tuberous-sclerosis-complex-and-sporadic-lam-107787https://curecurrent.com/trials/cannabis-for-spasticity-in-multiple-sclerosis-107788https://curecurrent.com/trials/factors-that-influence-compliance-with-disease-modifying-therapy-in-multiple-sclerosis-107789https://curecurrent.com/trials/t-cell-vaccination-in-multiple-sclerosis-ms-107790https://curecurrent.com/trials/evaluation-of-efficiency-of-ritalin-in-multiple-sclerosis-ms-patients-107791https://curecurrent.com/trials/effects-of-spinal-cord-injury-on-female-sexual-response-107792https://curecurrent.com/trials/the-efficacy-and-safety-of-escitalopram-for-depression-in-multiple-sclerosis-107793https://curecurrent.com/trials/combination-therapy-provigil-avonex-to-treat-cognitive-problems-in-ms-107794https://curecurrent.com/trials/tcv-01-002-t-cell-vaccination-in-the-treatment-of-probable-multiple-sclerosis-107795https://curecurrent.com/trials/yoga-effect-on-attention-in-aging-multiple-sclerosis-107796https://curecurrent.com/trials/natural-antioxidants-in-the-treatment-of-multiple-sclerosis-107797https://curecurrent.com/trials/omega-3-fatty-acid-treatment-in-multiple-sclerosis-107798https://curecurrent.com/trials/gait-evaluation-in-multiple-sclerosis-patients-treated-with-glatiramer-acetate-107799https://curecurrent.com/trials/short-term-effects-of-medicinal-cannabis-therapy-on-spasticity-in-multiple-sclerosis-107800https://curecurrent.com/trials/measuring-the-balance-improvement-on-multiple-sclerosis-patients-after-a-short-training-period-with-an-apos-all-phase-of-107801https://curecurrent.com/trials/optic-neuritis-treatment-trial-ontt-107802https://curecurrent.com/trials/longitudinal-optic-neuritis-study-lons-107803https://curecurrent.com/trials/treatment-of-multiple-sclerosis-using-over-the-counter-inosine-107804https://curecurrent.com/trials/combination-therapy-of-betaseron-prograf-in-multiple-sclerosis-107805https://curecurrent.com/trials/fatigue-treatment-using-provigil-107806https://curecurrent.com/trials/infections-and-autoimmunity-autobodies-screening-in-multiple-sclerosis-107807https://curecurrent.com/trials/multimodal-mri-in-multiple-sclerosis-ms-reliability-and-follow-up-107808https://curecurrent.com/trials/sleep-disorders-in-patients-with-multiple-sclerosis-107809https://curecurrent.com/trials/evaluation-of-a-new-therapeutic-strategy-in-early-and-active-relapsing-remitting-multiple-sclerosis-107810https://curecurrent.com/trials/a-safety-study-of-combination-treatment-with-avonex-and-zocor-in-relapsing-remitting-multiple-sclerosis-107811https://curecurrent.com/trials/use-of-cannabinoids-in-patients-with-multiple-sclerosis-107812https://curecurrent.com/trials/a-safety-study-of-combination-treatment-with-avonex-and-placebo-controlled-dosing-of-topamax-in-relapsing-remitting-mult-107813https://curecurrent.com/trials/safety-and-tolerability-of-interferon-beta-1a-and-estroprogestins-association-in-ms-patients-107814https://curecurrent.com/trials/phase-iii-randomized-double-blind-sham-controlled-study-of-plasma-exchange-for-acute-severe-attacks-of-inflammatory-demy-107815https://curecurrent.com/trials/phase-i-pilot-study-of-total-body-irradiation-anti-thymocyte-globulin-and-cyclophosphamide-followed-by-syngeneic-or-auto-107816https://curecurrent.com/trials/phase-i-study-of-high-dose-cyclophosphamide-and-total-body-irradiation-with-t-lymphocyte-depleted-autologous-peripheral-107817https://curecurrent.com/trials/antibiotic-treatment-trial-directed-against-chlamydia-pneumonia-in-multiple-sclerosis-107818https://curecurrent.com/trials/a-maintenance-extension-of-phase-i-pilot-study-of-chimeric-anti-cd4-antibody-m-t412-in-patients-with-multiple-sclerosis-107819https://curecurrent.com/trials/phase-iii-randomized-double-blind-placebo-controlled-study-of-copolymer-1-for-relapsing-remitting-multiple-sclerosis-107820https://curecurrent.com/trials/study-of-creatine-monohydrate-in-patients-with-amyotrophic-lateral-sclerosis-107821https://curecurrent.com/trials/efficacy-and-safety-study-of-qaw039-in-patients-with-severe-asthma-inadequately-controlled-with-standard-of-care-asthma-107822https://curecurrent.com/trials/testing-the-effects-of-temperature-humidity-on-children-with-and-without-asthma-in-an-environmental-climatic-chamber-107823https://curecurrent.com/trials/long-term-effect-of-dupilumab-in-n-erd-107824https://curecurrent.com/trials/co-morbidity-and-refractory-asthma-uk-severe-asthma-registry-107825https://curecurrent.com/trials/a-long-term-study-of-kt-621-administered-orally-to-participants-with-asthma-previously-enrolled-in-a-kt-621-asthma-study-107826https://curecurrent.com/trials/a-study-to-investigate-gb-0895-adjunctive-therapy-in-adults-and-adolescents-with-severe-uncontrolled-asthma-solairia-2-107827https://curecurrent.com/trials/a-study-to-investigate-gb-0895-adjunctive-therapy-in-adults-and-adolescents-with-severe-uncontrolled-asthma-solairia-1-107828https://curecurrent.com/trials/clinical-and-demographic-features-of-patients-with-uncontrolled-severe-asthma-in-russia-corsar-107829https://curecurrent.com/trials/a-study-to-learn-about-the-study-medicine-called-tilrekimig-in-people-with-severe-asthma-107830https://curecurrent.com/trials/effect-of-video-game-based-breathing-exercises-on-respiratory-dysfunction-in-acos-107831https://curecurrent.com/trials/pragmatic-open-label-randomized-clinical-trial-of-ff-umec-vi-vs-non-ellipta-usual-care-ics-laba-for-adult-participants-w-107832https://curecurrent.com/trials/smart-home-feasibility-trial-107833https://curecurrent.com/trials/a-study-of-kt-621-administered-orally-to-adult-participants-with-moderate-to-severe-eosinophilic-asthma-107834https://curecurrent.com/trials/a-study-to-investigate-the-efficacy-and-safety-of-tezepelumab-compared-with-placebo-in-children-5-to-12-years-old-with-s-107835https://curecurrent.com/trials/a-randomized-double-blind-placebo-controlled-trial-on-efficacy-and-safety-of-fluticasone-propionate-albuterol-sulfate-co-107836https://curecurrent.com/trials/open-label-study-to-assess-reduction-of-background-asthma-medication-while-sustaining-asthma-control-and-clinical-remiss-107837https://curecurrent.com/trials/study-of-hospitalised-patients-with-acute-respiratory-conditions-107838https://curecurrent.com/trials/a-study-to-assess-and-compare-safety-and-tolerability-of-3-months-treatment-with-salbutamol-administered-via-mdi-contain-107839https://curecurrent.com/trials/a-research-study-of-house-dust-mite-hdm-slit-tablet-for-the-treatment-of-hdm-allergy-in-chinese-participants-aged-12-65-107840https://curecurrent.com/trials/safety-and-efficacy-comparison-between-chf5993-100-6-12-5-g-pmdi-to-seretide-evohaler-125-25-g-pmdi-in-adolescent-subjec-107841https://curecurrent.com/trials/acoustic-waveform-respiratory-evaluation-107842https://curecurrent.com/trials/prevent-wheeze-trial-107843https://curecurrent.com/trials/a-study-to-learn-about-the-study-medicine-called-pf-07275315-in-people-with-moderate-to-severe-asthma-107844https://curecurrent.com/trials/longitudinal-observational-study-of-severe-asthma-107845https://curecurrent.com/trials/long-term-safety-and-efficacy-evaluation-of-subcutaneous-amlitelimab-in-adult-participants-with-moderate-to-severe-asthm-107846https://curecurrent.com/trials/educational-needs-of-patients-with-severe-asthma-on-targeted-immunotherapies-107847https://curecurrent.com/trials/coincide-cardineurovascular-disease-and-obstructive-airway-disease-107848https://curecurrent.com/trials/a-study-assessing-the-effect-of-dupilumab-on-inducing-clinical-remission-in-asthma-107849https://curecurrent.com/trials/tgf-beta-and-susceptibility-to-rsv-107850https://curecurrent.com/trials/asthma-ctrl-smart-trial-107851https://curecurrent.com/trials/evaluation-of-safety-side-effects-and-how-the-drug-inhaled-chf10136-is-absorbed-modified-and-removed-from-the-body-in-he-107852https://curecurrent.com/trials/modeling-bronchial-epithelium-in-severe-asthma-with-human-induced-pluripotent-stem-cells-ipsc-107853https://curecurrent.com/trials/asthma-crisis-in-paediatrics-impact-of-a-care-pathway-in-primary-and-hospital-care-107854https://curecurrent.com/trials/safety-and-feasibility-study-of-intranasal-mesenchymal-trophic-factor-mtf-for-treatment-of-asthma-107855https://curecurrent.com/trials/study-of-inhaled-aro-rage-in-allergen-induced-mild-asthma-107856https://curecurrent.com/trials/the-allergen-reduction-and-child-health-study-archs-107857https://curecurrent.com/trials/5htp-regulation-of-asthma-in-children-107858https://curecurrent.com/trials/a-study-to-test-if-a-fixed-dose-combination-of-fluticasone-propionate-albuterol-sulfate-is-effective-in-preventing-asthm-107859https://curecurrent.com/trials/scaling-up-the-integrated-care-pathway-for-acute-asthma-to-all-osakidetza-pediatric-services-through-a-cluster-randomize-107860https://curecurrent.com/trials/lung-resident-memory-th2-cells-in-asthma-107861https://curecurrent.com/trials/a-study-to-investigate-the-efficacy-and-safety-of-gsk5784283-compared-with-placebo-in-participants-with-uncontrolled-ast-107862https://curecurrent.com/trials/a-study-to-compare-safety-of-4-weeks-exposure-to-propellants-hydrofluoroalkane-1-1-difluoroethane-hfa-152a-and-hfa-1-1-1-107863https://curecurrent.com/trials/a-study-to-compare-the-efficacy-safety-and-tolerability-of-ff-umec-vi-with-ff-vi-in-12-17-year-olds-with-asthma-107864https://curecurrent.com/trials/a-multicentre-randomised-double-blind-parallel-group-placebo-controlled-time-to-first-asthma-exacerbation-phase-iii-effi-107865https://curecurrent.com/trials/tezspire-tezepelumab-asthma-japan-post-marketing-study-pms-107866https://curecurrent.com/trials/thoracic-spine-rotation-stretching-and-scapular-retraction-in-asthma-patients-107867https://curecurrent.com/trials/activation-and-function-of-eosinophils-in-conditions-with-blood-or-tissue-eosinophilia-107868https://curecurrent.com/trials/induced-tolerogenic-dendritic-cells-as-modulators-of-allergic-asthma-107869https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-and-safety-of-qvm149-indacaterol-acetate-glycopyrronium-bromide-mometasone-furoate-vers-107870https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-and-safety-of-qmf149-indacaterol-acetate-mometasone-furoate-versus-budesonide-in-childr-107871https://curecurrent.com/trials/a-study-of-jnj-95597528-in-participants-with-inadequately-controlled-moderate-to-severe-asthma-107872https://curecurrent.com/trials/a-study-to-investigate-the-efficacy-and-safety-of-gsk5784283-compared-with-placebo-in-participants-with-uncontrolled-ast-107873https://curecurrent.com/trials/benralizumab-airway-remodeling-study-in-severe-eosinophilic-asthmatics-107874https://curecurrent.com/trials/sustained-asthma-remission-and-reduced-relapse-using-a-comprehensive-management-strategy-sarre-coms-107875https://curecurrent.com/trials/study-to-compare-the-effects-of-z7200-and-symbicort-turbohaler-on-respiratory-imaging-parameters-in-asthmatic-patients-107876https://curecurrent.com/trials/dose-range-finding-study-to-assess-efficacy-and-safety-of-tozorakimab-in-adults-with-uncontrolled-asthma-on-medium-to-hi-107877https://curecurrent.com/trials/evaluation-of-the-asthma-management-program-to-promote-activity-for-students-in-schools-asthma-pass-107878https://curecurrent.com/trials/a-study-evaluating-disease-characteristics-and-outcomes-in-participants-with-asthma-in-routine-clinical-practice-107879https://curecurrent.com/trials/canadian-consortium-on-airway-mucus-occlusions-in-asthma-copd-and-chronic-cough-107880https://curecurrent.com/trials/real-world-effectiveness-of-depemokimab-in-allergic-bronchopulmonary-aspergillosis-with-severe-eosinophilic-asthma-107881https://curecurrent.com/trials/impact-of-gdmt-in-uncontrolled-asthma-patients-receiving-mhd-inhaled-corticosteroids-long-acting-2-agonist-107882https://curecurrent.com/trials/microglia-activation-in-asthma-107883https://curecurrent.com/trials/novel-method-for-removal-of-orally-deposited-inhaled-fluticasone-propionate-107884https://curecurrent.com/trials/post-exacerbation-asthma-clinic-telecare-intervention-to-reduce-recurrent-exacerbations-107885https://curecurrent.com/trials/env-294-for-moderate-to-severe-asthma-a-12-week-study-in-adults-107886https://curecurrent.com/trials/a-24-week-prospective-open-label-multicenter-single-arm-rpms-study-in-real-world-setting-for-atectura-107887https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pk-and-immunogenicity-of-apg777-in-adults-with-asthma-107888https://curecurrent.com/trials/breztri-regulatory-post-marketing-surveillance-in-korea-107889https://curecurrent.com/trials/early-diagnosis-and-treatment-of-undiagnosed-asthma-or-copd-the-ucap-2-trial-107890https://curecurrent.com/trials/study-of-formoterol-6-mcg-fluticasone-125-mcg-by-eurofarma-laborat-rios-s-a-versus-alenia-6-mcg-200-mcg-in-patients-with-107891https://curecurrent.com/trials/evolve-study-the-real-life-clinical-practice-with-tezepelumab-in-greece-107892https://curecurrent.com/trials/a-multicenter-randomized-parallel-two-period-non-inferiority-study-of-eurofarmavsalenia-in-asthma-and-copd-treatment-107893https://curecurrent.com/trials/n-watch-nottingham-wheeze-assessment-in-tidal-children-107894https://curecurrent.com/trials/a-study-to-evaluate-brenipatide-compared-with-placebo-in-adult-participants-with-uncontrolled-moderate-to-severe-asthma-107895https://curecurrent.com/trials/roll-over-study-for-participants-who-have-completed-a-previous-clinical-study-with-benralizumab-fasenra-and-benefit-from-107896https://curecurrent.com/trials/study-of-lunsekimig-sar443765-compared-with-placebo-in-adults-with-high-risk-asthma-107897https://curecurrent.com/trials/camp-air-efficacy-and-cost-effectiveness-in-urban-adolescents-107898https://curecurrent.com/trials/long-term-safety-and-efficacy-evaluation-of-lunsekimig-sar443765-in-adult-participants-with-asthma-107899https://curecurrent.com/trials/assess-accuracy-of-primary-care-asthma-and-copd-diagnosis-using-oscillometry-and-feno-vs-specialist-diagnosis-107900https://curecurrent.com/trials/detection-of-cav1-calcium-channels-in-inflammatory-cells-of-asthmatic-children-107901https://curecurrent.com/trials/resources-and-education-for-addressing-chronic-health-reach-107902https://curecurrent.com/trials/effect-of-cpap-treatment-in-patients-with-severe-uncontrolled-asthma-the-asthma-sleep-trial-107903https://curecurrent.com/trials/a-study-to-investigate-efficacy-and-safety-of-pt027-compared-with-pt007-in-symptomatic-chinese-adults-with-asthma-107904https://curecurrent.com/trials/primary-care-asthma-feno-trial-107905https://curecurrent.com/trials/a-real-life-observational-study-in-severe-eosinophilic-asthma-adult-participant-treated-with-benralizumab-in-italy-107906https://curecurrent.com/trials/smart-implementation-effectiveness-trial-2-107907https://curecurrent.com/trials/smart-implementation-effectiveness-trial-1-107908https://curecurrent.com/trials/bioequivalence-study-of-aju-r713-and-r713r-in-healthy-adult-volunteers-107909https://curecurrent.com/trials/genes-soy-isoflavones-and-virus-107910https://curecurrent.com/trials/structured-nursing-intervention-for-adults-with-poorly-controlled-asthma-a-pilot-study-107911https://curecurrent.com/trials/quartz-comparative-effectiveness-of-switching-from-albuterol-to-albuterol-budesonide-versus-adding-low-dose-ics-or-ltra-107912https://curecurrent.com/trials/a-comparison-of-diagnostic-testing-modalities-in-the-assessment-of-asthma-107913https://curecurrent.com/trials/randomised-control-trial-to-understand-whether-prescribing-choice-for-inhalers-is-influenced-by-knowledge-of-the-carbon-107914https://curecurrent.com/trials/characterization-and-clinical-outcomes-of-severe-asthma-patients-in-israel-treated-with-benralizumab-sail-b-107915https://curecurrent.com/trials/artificially-intelligent-robot-control-107916https://curecurrent.com/trials/t2air-real-world-efficacy-and-safety-of-biologics-targeting-type-2-inflammation-in-asthma-and-copd-107917https://curecurrent.com/trials/rademikibart-add-on-treatment-of-an-acute-asthma-exacerbation-seabreeze-stat-asthma-107918https://curecurrent.com/trials/pulmonary-stimulation-for-asthma-relief-107919https://curecurrent.com/trials/real-world-evaluation-of-tezepelumab-for-chronic-rhinosinusitis-with-nasal-polyps-in-russia-107920https://curecurrent.com/trials/fasenra-an-asthma-study-107921https://curecurrent.com/trials/post-vent-the-sequelae-personalized-prognostic-modeling-for-consequences-of-neonatal-intermittent-hypoxemia-in-preterm-i-107922https://curecurrent.com/trials/digital-delivery-of-person-centered-transitional-care-107923https://curecurrent.com/trials/reducing-asthma-attacks-in-disadvantaged-school-children-with-asthma-107924https://curecurrent.com/trials/boosting-referrals-to-asthma-specialists-for-patients-seen-at-the-emergency-room-for-an-asthma-exacerbation-107925https://curecurrent.com/trials/explore-the-diagnostic-value-of-bronchodilation-test-with-portable-oscillometry-in-asthma-diagnosis-107926https://curecurrent.com/trials/study-of-aro-muc5ac-in-healthy-subjects-and-patients-with-muco-obstructive-lung-disease-107927https://curecurrent.com/trials/a-randomised-feasibility-study-of-cpap-in-large-airway-collapse-107928https://curecurrent.com/trials/forced-oscillations-technique-during-a-metacholine-test-in-children-107929https://curecurrent.com/trials/childhood-allergy-and-the-neonatal-environment-107930https://curecurrent.com/trials/development-and-validation-of-the-indian-asthma-care-bundle-for-reducing-readmission-and-improving-post-hospitalisation-107931https://curecurrent.com/trials/childhood-infection-and-immunity-longitudinal-cohort-107932https://curecurrent.com/trials/diagnosing-asthma-with-clinically-accessible-non-invasive-and-efficient-tests-a-child-inclusive-translational-investigat-107933https://curecurrent.com/trials/comparison-between-chf5993-pmdi-200-6-12-5-g-hfa-152a-vs-chf5993-pmdi-200-6-12-5-g-hfa-134a-in-subjects-with-asthma-trec-107934https://curecurrent.com/trials/effects-of-beclometasone-dipropionate-formoterol-fumarate-via-next-haler-in-a-real-world-study-on-asthma-control-107935https://curecurrent.com/trials/a-randomized-phase-ib-double-blind-placebo-controlled-study-to-evaluate-the-safety-and-efficacy-of-skb575-hbm7575-in-par-107936https://curecurrent.com/trials/phase-ii-trial-of-rc1416-injection-in-asthma-107937https://curecurrent.com/trials/fasenra-pediatric-japan-post-marketing-study-pms-107938https://curecurrent.com/trials/chest-a-collaboration-with-community-health-centers-to-implement-smart-for-asthma-107939https://curecurrent.com/trials/assessment-of-small-airways-involvement-in-asthma-atlantis-107940https://curecurrent.com/trials/rig-101-trial-in-healthy-adults-and-adults-with-asthma-107941https://curecurrent.com/trials/asthmaxcel-voice-study-107942https://curecurrent.com/trials/observational-study-on-therapy-pathways-of-asthamics-treated-with-ics-laba-lama-therapy-in-a-real-world-setting-107943https://curecurrent.com/trials/sample-collections-from-the-airways-of-asthmatic-patients-107944https://curecurrent.com/trials/a-study-to-investigate-the-effect-on-lung-function-of-bda-formulated-with-a-next-generation-propellant-compared-with-an-107945https://curecurrent.com/trials/efficacy-and-safety-of-cp006-inhalation-powder-in-participants-with-asthma-107946https://curecurrent.com/trials/a-study-to-evaluate-the-treatment-pattern-of-moderate-to-severe-asthma-patients-in-china-107947https://curecurrent.com/trials/bioequivalence-study-of-budesonide-formoterol-inhalation-powder-in-healthy-participants-107948https://curecurrent.com/trials/impact-of-sleep-duration-on-immune-balance-in-urban-children-with-asthma-107949https://curecurrent.com/trials/the-puerto-rico-asthma-integrated-response-program-pr-air-107950https://curecurrent.com/trials/inhaler-lung-deposition-in-chronic-obstructive-pulmonary-disease-copd-107951https://curecurrent.com/trials/step-phase-iiib-study-of-benralizumab-to-step-down-maintenance-therapy-in-patients-with-severe-eosinophilic-asthma-107952https://curecurrent.com/trials/using-a-digital-spacer-for-inhaler-technique-education-in-pediatric-asthma-107953https://curecurrent.com/trials/phase-3b-study-in-patients-with-severe-asthma-treated-with-tezepelumab-107954https://curecurrent.com/trials/evaluate-pharmacokinetics-and-safety-of-slow-release-dhea-107955https://curecurrent.com/trials/a-study-to-learn-how-different-amounts-of-the-study-medicine-called-pf-08103402-are-tolerated-and-act-in-the-body-in-hea-107956https://curecurrent.com/trials/phase-1-study-evaluating-safety-and-pharmacokinetics-of-asy202-in-adults-with-asthma-107957https://curecurrent.com/trials/the-cox-2-gene-and-the-immune-system-107958https://curecurrent.com/trials/nhales-natural-history-of-asthma-with-longitudinal-environmental-sampling-107959https://curecurrent.com/trials/new-approaches-for-empowering-studies-of-asthma-in-populations-of-african-descent-107960https://curecurrent.com/trials/efficacy-of-high-dose-continuous-intravenous-magnesium-sulfate-infusion-vs-standard-intravenous-magnesium-sulfate-therap-107961https://curecurrent.com/trials/smart-inhaler-and-remote-asthma-management-in-adolescents-with-intellectual-and-developmental-disabilities-107962https://curecurrent.com/trials/combination-of-high-flow-nasal-oxygen-optiflow-and-vibrating-membrane-nebuliser-aerogen-in-the-pre-hospital-setting-befo-107963https://curecurrent.com/trials/ginger-s-therapeutic-potential-in-asthma-107964https://curecurrent.com/trials/asthma-lung-sounds-with-wearable-stethoscope-107965https://curecurrent.com/trials/real-world-study-assessing-efficacy-of-tezepelumab-in-patients-with-severe-asthma-regardless-of-phenotype-in-russia-107966https://curecurrent.com/trials/a-non-interventional-prospective-study-with-benralizumab-107967https://curecurrent.com/trials/a-phase-1-trial-of-amg-691-in-healthy-chinese-and-japanese-volunteers-107968https://curecurrent.com/trials/budesonide-formoterol-inhalation-powder-in-adults-with-asthma-107969https://curecurrent.com/trials/a-study-evaluating-the-effect-of-inhaled-pt007-as-mdi-versus-placebo-mdi-and-ventolin-evohaler-on-lung-function-in-adult-107970https://curecurrent.com/trials/rademikibart-iv-for-acute-asthma-and-copd-exacerbation-107971https://curecurrent.com/trials/a-phase-ii-study-to-investigate-lung-function-with-2-different-doses-of-inhaled-glycopyrronium-taken-with-bff-compared-t-107972https://curecurrent.com/trials/a-study-of-depemokimab-in-participants-of-6-to-11-years-of-age-107973https://curecurrent.com/trials/expression-of-tslp-isoforms-in-asthma-107974https://curecurrent.com/trials/this-study-aims-to-compare-asthma-control-in-children-monitored-with-feno-against-a-historical-cohort-without-feno-secon-107975https://curecurrent.com/trials/self-management-of-asthma-by-forced-oscillation-technique-107976https://curecurrent.com/trials/withania-somnifera-for-moderate-to-severe-persistent-asthma-107977https://curecurrent.com/trials/a-study-to-assess-the-potential-for-airway-sensitivity-reactions-with-propellants-hfa-152a-test-and-hfa-134a-reference-a-107978https://curecurrent.com/trials/tezepelumab-pro-study-107979https://curecurrent.com/trials/registry-of-asthma-characterization-and-recruitment-3-racr3-107980https://curecurrent.com/trials/creation-of-a-biological-collection-of-bronchiai-and-pulmonary-tissues-from-surgical-waste-107981https://curecurrent.com/trials/early-high-flow-oxygen-therapy-with-nebulized-beta-2-agonist-using-a-vibrating-mesh-for-the-management-of-moderate-to-se-107982https://curecurrent.com/trials/to-identify-persons-who-are-susceptible-to-wsp-induced-inflammation-and-examine-the-role-of-gstm1-and-other-factors-in-t-107983https://curecurrent.com/trials/symptom-driven-ics-laba-therapy-for-adolescent-patients-with-asthma-non-adherent-to-daily-maintenance-inhalers-107984https://curecurrent.com/trials/washington-university-severe-asthma-research-program-iii-107985https://curecurrent.com/trials/efficacy-of-l-menthol-on-breathlessness-in-asthma-107986https://curecurrent.com/trials/symptom-driven-ics-laba-therapy-for-patients-with-asthma-non-adherent-to-daily-maintenance-inhalers-107987https://curecurrent.com/trials/tqc2731-clinical-trial-for-the-treatment-of-severe-asthma-with-injection-107988https://curecurrent.com/trials/pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-glycopyrronium-bromide-in-children-6-to-less-than-12-years-107989https://curecurrent.com/trials/respiratory-admittance-by-oscillometry-in-children-107990https://curecurrent.com/trials/real-world-and-genomic-data-based-asthma-insight-through-network-analysis-107991https://curecurrent.com/trials/a-translational-study-to-describe-clinical-characteristics-biomarkers-and-to-identify-phenotypes-and-endotypes-associate-107992https://curecurrent.com/trials/bilevel-positive-airway-pressure-bpap-for-severe-asthma-107993https://curecurrent.com/trials/changes-in-eosinophil-cationic-protein-and-sputum-eosinophils-following-allergen-immunotherapy-107994https://curecurrent.com/trials/asthma-exacerbations-respiratory-management-international-survey-107995https://curecurrent.com/trials/physical-activity-promotion-and-clinical-remission-in-severe-asthma-107996https://curecurrent.com/trials/a-study-of-efficacy-and-safety-of-depemokimab-compared-with-placebo-in-adults-and-adolescents-with-at-risk-type-2-asthma-107997https://curecurrent.com/trials/beclometasone-dipropionate-and-formoterol-inhalation-aerosol-for-asthma-107998https://curecurrent.com/trials/characterization-of-adult-subjects-for-asthmatic-research-studies-107999https://curecurrent.com/trials/clinical-and-autonomic-efficacy-of-digital-gamified-diaphragmatic-training-in-pediatric-pulmonary-rehabilitation-108000https://curecurrent.com/trials/predictive-factors-for-a-positive-exercise-bronchial-hyperresponsiveness-test-108001https://curecurrent.com/trials/evaluating-the-efficacy-and-safety-of-pt027-compared-with-pt007-administered-as-needed-in-participants-12-to-18-years-of-108002https://curecurrent.com/trials/fcv-vs-vcv-in-obstructive-and-asthmatic-patients-108003https://curecurrent.com/trials/efficacy-and-safety-of-subcutaneous-dupilumab-in-participants-with-asthma-asthmatic-wheeze-aged-2-to-6-years-liberty-ast-108004https://curecurrent.com/trials/effects-of-wet-cupping-therapy-in-patients-with-asthma-108005